FORESEE Pharmaceuticals

2024 Sustainability Report

ForeSee

We develop technologies and medicines that provide patients with better comfort, compliance, convenience and ultimately cures.

Contents

About this Report

Guidelines for Compiling the Report

The report has been prepared by Foresee Pharmaceuticals Co., Ltd. (hereinafter referred to as “Foresee,” “the Company,” or “we”) in accordance with the latest GRI Standards issued by the Global Reporting Initiative (GRI) and the “Taipei Exchange Rules Governing the Preparation and Filing of Sustainability Reports by TPEx Listed Companies” published by the Taipei Exchange. And references the Task Force on Climate-related Financial Disclosures (TCFD) framework for disclosing information related to climate risks as well as the disclosure metrics for the Biotechnology and Pharmaceuticals industry as established by the Sustainability Accounting Standards Board (SASB) in this Report. A corresponding index is provided at the end of the report to facilitate quick reference and retrieval.

Scope and Boundary

This report primarily discloses information related to Foresee Pharmaceuticals Co., Ltd., the Taiwan parent company (Taipei office and laboratory). Where feasible, it also includes information from subsidiaries in the United States, Canada, and Australia, with specific notations made within the text. The financial data in this report has been audited by PwC Taiwan in accordance with the International Financial Reporting Standards (IFRS) and is consistent with the publicly disclosed financial data. Environmental and social data are provided by the respective internal departments of the Company. If any data is estimated, it will be clearly explained in the text.

Restatements of Information

Compared with the previous version of this report, there are no significant changes in material topics or boundaries. The data restatements include the correction of the misstated employee turnover rate for 2023.

Report Overview and Publication Frequency

The data mainly covers the period from January 1, 2024, to December 31, 2024, presenting the Company's performance in economic, environmental, social, and corporate governance aspects. If any information covers multiple years, it will be specifically noted in the Report. The 2023 Sustainability Report is the first issuance, so there are no issues of data restatement. The report was finalized after review and approval by the Company's Corporate Governance Officer, submitted to the Board of Directors, and verified by Great Certification. To fully present the mid-to long-term project performance of the Company and ensure the information is comparable and timely, the report is planned for annual issuance.

Previous Publication：August 2024

Current Publication：August 2025

Independent Assurance

Information	Standards Followed	Assurance Provider
Sustainability Information	AA 1000 V3 Type 1 - Moderate level	GREAT International Certification Co., Ltd.
	GRI Standards 2021	
Financial Data	International Financial Reporting Standards (IFRS)	PricewaterhouseCoopers (PwC) Taiwan

Contact us

We welcome any suggestions regarding this report. Please contact us to help us continuously enhance our practices.

Accountability	Sustainable Development Group
Address	9F-2, No. 19-3, Sanchong Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)
Phone	886-2-7750-0188
Email	esg@foreseepharma.com
Company Website	www.foreseepharma.com

Message from the Chairman

In 2024, we have witnessed the profound impacts of climate change on the global ecological environment. Extreme weather events such as hurricanes, heavy rainfall, wildfires, and heat waves have occurred with increasing frequency, causing not only significant losses to human life and property but also posing severe challenges to global ecosystems and economic development. Mitigating the worsening impacts of climate change has become the most urgent global objective in ESG sustainability efforts. Harmony with the earth's environment and social inclusiveness form the cornerstone of Foresee Pharma's sustainable operations.

Persistence, Respect, Mission, Passion, Humility, and Integrity are the core values of Foresee. With the greatest passion and spirit of scientists, we remain committed to continuous innovation and R&D. Enhancing the quality of care for patients is the mission of the Foresee team. We strive to improve patients' quality of life and to develop effective treatment solutions through innovative research.

Our R&D efforts focus on two major areas: The SIF-LAI technology platform, targeting niche markets with long-acting injectable formulations; and First-in-class or best-in-class innovative small-molecule drugs, addressing urgent unmet needs in rare and severe diseases.

The maturity and commercial value of the SIF-LAI technology have gradually emerged following the successful global licensing of CAMCEVI®, the approval of CAMCEVI 42mg in the United States, Canada, Europe, Taiwan, Israel, and the United Kingdom, as well as its successful market launches in the U.S. and Germany. Looking ahead, whether it is the marketing application for the three-month formulation, the development of new indications, or the pipeline of other new drugs developed based on the SIF-LAI platform, all endeavors are expected to progress with greater efficiency and promising growth prospects.

In 2024, we successfully submitted the New Drug Application (NDA) for CAMCEVI 21mg to the U.S. FDA. In terms of innovative small-molecule new drug (NCE) development, the Phase I clinical trial (syMMPonia) of the MMP-12 inhibitor FP-020 (Linvemastat) was approved by the Human Research Ethics Committee (HREC) in Australia, and subject dosing has commenced. Meanwhile, the Phase II clinical trial (WINDWARD) of the ALDH2 activator FP-045 (Mirivadelgat), targeting pulmonary hypertension associated with interstitial lung disease, has been approved for execution by both the U.S. FDA and the Taiwan Food and Drug Administration (TFDA).

Foresee values communication with global stakeholders. In the 2024 Corporate Governance Evaluation, among 773 TPEx-listed companies, our results ranked within the top 6–20%. We will continue striving to respond to the support and expectations of society and our stakeholders. This year, through partnerships with seven social welfare organizations, we provided assistance to underprivileged families and children in rural and economically disadvantaged areas.

We are committed to providing comfort, compliance, convenience, and cure, taking concrete actions to improve patients' quality of life. This is not only our mission but also the core of all our operations and innovations. With determination, conviction, and love, we move forward steadfastly, aspiring to bring positive change to the world through biotechnology and to realize the values of sustainability.

Chairman & CEO, Ben Chien

1.Sustainable Development & Management

1.1 Business Overview

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee's R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable (LAI) technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs.

Foresee's product portfolio includes late and early-stage programs. Camcevi 42 mg, or the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan, Israel, and the UK and was launched in the U.S. and DE. Additionally, the U.S. NDA for the 3-month version of Camcevi has been submitted and accepted for review as well as the EU regulatory submission. For the second indication of Camcevi 6-month LAI formulation, central precocious puberty (CPP), the Casppian Phase 3 clinical study is ongoing. Camcevi 6-month LAI formulation is also being developed in a Phase 3 clinical trial in premenopausal breast cancer in China.

Aderamastat (FP-025), a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study had positive outcomes, with future development in rare immune-fibrotic diseases. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, was completed in a Phase 1 study in healthy volunteers, with development targeted at severe asthma, COPD, and IBD. Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients has been initiated. www.foresee pharma.com。

Company	Foresee Pharmaceuticals Co., Ltd. (TPEx : 6576)
Headquarters Address	9F-2, No. 19-3, Sanchong Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)
Capital	1, 547,878 (in thousands of New Taiwan Dollars)
Operational Locations by Region	Taiwan (Taipei) USA (Delaware) Canada (Quebec) Australia (Melbourne) 
Industry	Biotechnology & Pharmaceuticals SASB Standards Comparison - Disclosure Standards for the Biotechnology & Pharmaceuticals Industry
Primary Services	New drug development / CAMCEVI 42 mg
Annual Revenue	449,493 (in thousands of New Taiwan Dollars)

Management Philosophy and Outlook

Foresee's mission is to improve the quality of care through innovative drug development. Guided by the principles of COMFORT, COMPLIANCE, CONVENIENCE, and CURE, we are dedicated to providing patients with more effective and accessible treatment options. Through these efforts, we aim to enhance patients' quality of life and address unmet medical needs.

- Utilizing the SIF-LAI platform technology, improve upon the shortcomings of existing drugs and expand clinical applications to reduce R&D costs and shorten development timelines for faster market entry.
- Continuously explore various applications for its innovative new chemical entities (NCEs) under the same therapeutic mechanism, and develop innovative medicines targeting high-potential markets and unmet medical needs.
- Continuously pursue technology transfer for candidate drugs by utilizing existing drug development platforms. Actively seek new drug development projects externally and collaborate with domestic and international research institutions to identify and evaluate potential new drug development opportunities.

Industry Value Chain

Foresee's Upstream, Midstream, and Downstream includes domestic and international preclinical and clinical trial centers, active pharmaceutical ingredient (API) and excipient suppliers, pharmaceutical CDMO manufacturers, pharmaceutical companies, logistics and warehousing, and marketing channels. Foresee employs a high-efficiency drug development model that begins with drug screening. Before entering clinical trials, "Proof of Concept" studies are conducted. We then work with regulatory agencies such as the US FDA (Food and Drug Administration), the EU EMA (European Medicines Agency), and various Asian regulatory bodies, including Taiwan's CDE (Center for Drug Evaluation), South Korea's MFDS (Ministry of Food and Drug Safety), and China's NMPA (National Medical Products Administration). The aim to establish reasonable and expedited clinical and regulatory pathways through these negotiations, thereby reducing significant time and resources required to move from exploration to a candidate drug, while also mitigating development risks. Concurrently, we have established long-term, close partnerships with upstream and downstream collaborators (including licensing and co-marketing partners) to maximize the value and effectiveness of our research and development outcomes.

Participation in External Organizations

The company actively participates in various industry associations and organizations to foster positive interactions within the industry. Through the exchange of the latest information and sharing of experiences, the Company stays informed about industry developments.

External Association	Role
Taiwan Bio Industry Organization	Member
Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA)	Member
Institute for Biotechnology and Medicine Industry	Member
Taipei Biotech Association	Member



Sustainable Development Group

Foresee's Sustainable Development Group, established in 2022, is responsible for driving the company's sustainability initiatives. The Group is organized into five functional workgroups aligned with the sustainability strategy: "Corporate Governance," "Partnership Relations," "Friendly Workplace," "Social Care" and "Green Environment." Members of these workgroups are drawn from relevant business units. Planned initiatives include the development of sustainability policies and goals, related advocacy and training, as well as commitments to environmental protection and public welfare activities. Regular quarterly reports are submitted to the Board of Directors.



1.2 Stakeholder Engagement and Interaction

The Company, in accordance with the five principles of the AA1000 Stakeholder Engagement Standard (AA1000 SES)—Dependence, Responsibility, Influence, Diverse Perspectives, and Tension—has each department identify categories of stakeholders based on business interactions, the degree of mutual influence with Foresee, and frequency of engagement. Through internal discussions and benchmarking against industry peers, five key stakeholder groups with significant impact on Foresee have been identified. The Company has also established diverse communication channels to collect stakeholders' concerns and provide timely responses.

Step 1. Understanding Organizational Structure

Reference relevant industry standards, review organizational management activities, business relationships, and identify stakeholder processes to understand the overall organizational concept and related impacts.

Step 2. Identifying Actual and Potential Impacts

Based on the organization' s overall profile and relevant impact information, as well as the issues of concern to stakeholders, 15 sustainability-related topics have been selected for focus.

Step 3. Assessing the Significance of Impacts

By conducting internal and external stakeholder surveys, the "Stakeholder Impact Score" and the "Economic, Environmental, and Social Impact Scores" can be determined to perform a material analysis.

Step 4. Prioritizing the Reporting Sequence of Most Significant Impacts

Identified topics are ranked based on their significance and importance according to sustainability industry standards and consultants' evaluations. Ultimately, six material topics were selected for reporting.

AA1000 SES

AA1000 Stakeholder Engagement Standard





1.3 Materiality Assessment

The Sustainable Development Group issued questionnaires on 15 sustainability topics to stakeholders, including management. After statistical analysis, a materiality matrix was generated and discussed in Sustainable Development Group meetings in 2023. The top two topics from each of the three sustainability dimensions were selected as the Company's material topics for that year's sustainability report. In 2024, the Company continued to review the materiality assessment results identified in the previous year for further evaluation.

Foresee has not yet established specific performance indicators. At this stage, the assessment mechanisms and outcomes for each material topic are described in the respective chapters through narrative and tabular disclosures. The relevant page references are pages 11, 22, 29, 30, 35, and 39. The Company plans to develop performance indicators in the future to further strengthen the management of material topics.

Collection of Sustainability Issues

- GRI Standards
- Peer Reports / Industry Trends
- 15 Sustainability Topics

Impact Assessment

- Stakeholder Level of Concern
- Senior Management Assessment of Impact

Material Topics

- Economic Aspect
  - ✓ Innovative R&D
  - ✓ Operational Performance
- Social Aspect
  - ✓ Business Integrity & Ethical Management
  - ✓ Talent Attraction and Retention
- Environmental Aspect
  - ✓ Sustainable Supply Chain Management
  - ✓ Laboratory Waste Management

Periodic Review

- Stakeholder Feedback
- Review and Improvement Measures

Material Topics Matrix



Impact of Material Topics on the Value Chain

Material Topics	Positive Benefit	Unfavorable Outcome	Border Line	Response Chapter
Innovative R&D	• Enhance product differentiation and competitiveness • Create new revenue streams • Strengthen corporate image and technological leadership	• High resource and cost investment • High risk of innovation failure • Risks and disputes related to technology confidentiality	Shareholders/Investors, Drug Development Collaborators/Vendors, Employees, Communities/Groups	2.1 Innovation and R&D 2.3 Intellectual Property Management 2.4 Information Security Management
Operational Performance	• Increase profitability and resource utilization efficiency • Improve overall business competitiveness • Boost investor confidence and market valuation	• Low team morale • Loss of investor confidence	Shareholders/Investors, Employees, Competent Authorities	3.4 Operational Performance
Business Integrity & Ethical Management	• Build corporate reputation and image • Reduce legal and compliance risks • Strengthen trust with stakeholders	• Increased internal control and audit costs • Damage to corporate reputation	Shareholders/Investors, Drug Development Collaborators/Vendors, Employees, Competent Authorities	3.3 Regulatory Compliance 5.5 Business Integrity & Ethical Management
Talent Attraction and Retention	• Build a stable and professional team • Enhance innovation and execution capabilities • Lower recruitment and training costs	• Rising salary and benefits expenses • High turnover affecting innovation execution and company reputation	Employees, Communities/Groups	5.3 Talent Attraction and Retention 5.4 Talent Development
Laboratory Waste Management	• Reduce environmental pollution risks • Ensure regulatory compliance	• High handling costs and need for regulatory oversight resources • Poor management may draw public attention and harm corporate image	Drug Development Collaborators/Vendors, Employees, Competent Authorities, Communities/Groups	4.3 Laboratory Waste Management
Sustainable Supply Chain Management	• Mitigate supply chain disruption risks • Respond to market trends and attract long-term investment	• Time and cost required for supplier screening and management • Low supplier cooperation, product delays, and reduced revenue	Collaborators/Vendors, Employees	4.4 Sustainable Supply Chain Management

1.4 Stakeholder Communication

Foresee is committed to sustainability and aims to understand stakeholder perspectives while establishing open, transparent, and effective communication channels. Each responsible department communicates with stakeholders through various channels and gathers and consolidates concerns. This information is used as a reference for formulating and implementing the Company's social responsibility policies and related plans. Relevant sustainability performance data is regularly compiled and reported annually to the Board of Directors. The stakeholder engagement achievements for 2024 were presented in the Board report on November 13, 2024.

Stakeholder	Issues of Concern	Communication Channel	2024 Communication Performance
Shareholder/ Investors	• Corporate Governance • Operational Performance • Investment Plans • Risk Management • Sustainable Development Strategy	• Annual Report, Annual General Meeting (AGM), Bio-Asia Taiwan Exhibition: Annually • TWSE Market Observation Post System: Irregular • Investor conferences, Company Website: Irregular • IR Email, LinkedIn: Irregular	1. Invited to attend two in-person investor conferences. Uploaded the audio and video recording of the conference once. 2. Held 1 annual regular AGM. 3. Issued a total of 55 material information announcements and 32 press releases in both Chinese and English. 4. Participated in the 2024 Bio Asia-Taiwan Exhibition and the investment matchmaking program with domestic and international investors and potential business partners. 5. Responded to daily inquiries via the Investor Relations (IR) inbox and hotline. 6. Issued monthly press releases alongside revenue announcements to provide updates on CAMCEVI sales performance in the U.S. end market and enhance information transparency. 7. Ranked in the top 21% to 35% of listed companies based on the TWSE Corporate Governance Evaluation System results. 8. Set up a dedicated Investor Relations section on the Company's website, offering transparent updates on shareholder meetings, financial performance, and news releases. 9. Established a company LinkedIn page to regularly share relevant information and enhance international visibility for the Company.
Employees	• Compensation and Benefits • Labor Relations • Talent Development • Career Development • Occupational Health and Safety	• Employee Performance Evaluation: Annual • Internal Email Announcements: Irregular	1. Issued 15 internal announcements regarding employee benefits. 2. Regularly maintained and cleaned the office environment via professional services, including overall space, carpets/flooring, air conditioning, and water dispensers. 3. Annual employee health examination. 4. One employee performance evaluation conducted. 5. Offered flexible working hours and remote work options based on employees' job responsibilities to maintain work-life balance. 6. Employees participated in a total of 253 hours of internal & external training. 7. Conducted 6 internal control process briefing sessions for Taiwan/overseas employees.
Drug Development Collaborators/ Vendors	• Operational Performance • Corporate Vision • Supply Chain Management • Sustainable Development Strategy • Product Quality and Safety	• Supplier site visit: Irregular • Company Website: Irregular • E-mail: Irregular	1. Conducted 3 on-site visit of potential overseas CDMO partners. 2. Collaborated with 20 domestic and international academic and research institutions on preclinical development and clinical studies. 3. Regular weekly or bi-weekly meetings with suppliers to stay updated on production schedules. 4. Conducted 10 on-site inspections of active pharmaceutical ingredient vendors and CDMO pharmaceutical manufacturers. 5. Conducted the Annual Vendor Evaluation, assessing delivery timeliness, quality, price competitiveness, cooperation, and technical support.
Communities/Groups	• Charity Events • Sustainable Development Strategy	• Company Website: Irregular • E-mail: Irregular	1. Donated supplies to 11 charity organizations for disadvantaged groups. 2. In response to the Industrial Development Bureau's call for mutual support, joined the Nangang Software Park regional joint prevention organization.
Regulatory Authorities	• Sustainable Development Strategy • Regulatory Compliance	• Competent Authority Policy Advocacy Meeting/Irregular • TWSE Market Observation Post System/Irregular • Company Website/Irregular • Phone, E-mail, Official Correspondence/Irregular	1. Participated in the online briefing sessions organized by the Taipei Exchange (TPEx), including compliance matters, internal control systems, and insider shareholding regulations. 2. Communicated with the Industrial Development Bureau via Phone and email regarding R&D investment tax credits. 3. Communicated with the Taipei Exchange (TPEx) via Phone and email regarding issues with regulatory compliance. 4. Disclosed material information and various announcement filings to the TWSE Market Observation Post System. 5. Published the 2023 Sustainability Report in both Chinese and English. 6. Received 263 documents and sent 26 documents to government agencies.

2. Pharmaceutical Quality & Safety

Foresee is committed to advancing scientific progress and achieving significant breakthroughs and innovative therapies for human health. With the highest ethical standards, we develop safe and effective medications and ensure drug quality and safety through standardized procedures, offering high-quality treatment options that improve patients' quality of life.

R&D	Clinical	Manufacturing	Market Launch	Patient Medication
GLP	GCP	GMP	GDP	PV/GVP

2.1 Innovation and R&D

Our R&D team is fully dedicated to addressing complex problems and challenges. A steadfast passion for serving society lies at the heart of our team's core values. To address unmet medical needs with high market potential, Foresee adopts an efficient drug development model for drug screening. Before entering clinical trials, "Proof of Concept" studies are conducted, we then negotiate with the US FDA to establish reasonable and expedited clinical and regulatory pathways, thereby reducing significant time and resources required to move from exploration to a candidate drug, while also mitigating risks for new drug development.

The Company's R&D strategy combines the low-risk SIF-LAI platform technology for injectable drug development, with a high-demand, high-risk, and high-reward NCE innovative drug pipeline. At the appropriate development stages, we protect our R&D technologies and products through patent strategies and engage in product collaborations or licensing with reputable companies. This accelerates the commercialization process, delivering exceptional products to patients and healthcare providers while ensuring optimal returns for shareholders. The innovative R&D focused on two main areas:

(1) The Stabilized Injectable Formulation (SIF), targeting the specialty pharmaceuticals market, along with the injectable drugs developed through SIF. SIF technology can be applied to chronic diseases or conditions with poor patient compliance by providing long-acting injections, with therapeutic effects lasting for weeks or months. Foresee has successfully utilized SIF technology in the development of small molecules, peptides, and biologic drug development, including the approved and marketed product CAMCEVI®. Currently, products under development include FP-014 (Triptorelin, for prostate cancer) and FP-016 (for neurological disorders).

(2) The development of New Chemical Entities (NCEs) using rational drug design focuses on creating small molecule drugs with high selectivity, including MMP-12 inhibitors and ALDH2 activators, targeting rare and serious diseases with high unmet needs. Products currently under development are FP-025 (for sarcoidosis), FP-045 (for Fanconi anemia/pulmonary hypertension associated with interstitial lung disease), and their follow-on compounds FP-020 (asthma/chronic obstructive pulmonary disease/idiopathic pulmonary fibrosis) and FP-040 (CNS diseases).

Resources Invested in the Current Year	During the year, the parent company invested NT$853,886 thousand in R&D. Including consolidated subsidiaries, the total R&D expenditure amounted to NT$1,172,273 thousand.
Evaluation Mechanisms/ Results	The R&D departments regularly hold meetings to discuss research progress and conducts cross-departmental meetings for comprehensive evaluation and decision-making. All R&D projects follow an internal control R&D operation cycle, with audits of the R&D cycle management mechanism conducted according to the annual audit plan.

R&D Process and External References

- **SIF Technology Platform**

> Initial phase fundamental research, drug chemical structure (formulation) design, synthesis technique research, pre-clinical trials, and mid phase small-scale drug production trials and stability testing.

- **NCE New Drugs**

> Experimental planning and design, ongoing efficacy screening of new drug compounds, cellular testing, animal testing planning.

After the planning and testing phases for SIF and NCE R&D teams, the process continues with Phase I and II clinical trials, followed by product pilot testing and Phase III clinical trials. All these stages adhere to the internal control R&D cycle mechanism. Additionally, intellectual property patents are strategically filed to protect the company's crucial R&D technology assets.

- **External References**

1) Declaration of Helsinki
2) ICH Guideline For Good Clinical Practice (ICH-E6-GCP)
3) International standards relevant to clinical trials, including Good Clinical Practice, Good Laboratory Practice, and Good Manufacturing Practice (GxP)

R&D Plan

The Company's R&D expenditures are primarily allocated to clinical trials, product development, and pre-clinical research for new drug products and development programs. For 2025, Foresee plans to invest NT$1.68 billion, which is approximately 90% of operating expenses, to ensure the Company's competitive advantage.

- **Short to mid-term R&D Plans:**

1) Continue to conduct the Phase 3 clinical trial of FP-001 42 mg (i.e. CAMCEVI® 6-month LAI formulation) for the treatment of central precocious puberty.
2) Initiate the IND submissions for two Phase 3 clinical trials, with respective trials planned for the 6-month and 3-month LAI formulations of FP-014 (triptorelin) for the treatment of prostate cancer.
3) Prepare a Phase 2 clinical trial of FP-025 (aderamastat) for the treatment of rare immune-fibrotic diseases.
4) Continue to conduct the long-term toxicology studies of FP-020 (linvemastat, a follow-up compound of FP-025), and initiate a Phase 2 clinical trial for the treatment of asthma, and prepare a Phase 2 IND application for the treatment of inflammatory bowel disease (IBD).
5) Conduct the Phase 2 clinical trial of FP-045 (mirivadelgat) for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
6) Continue the development of new drug candidates emerging from both the SIF/NCE platform.

- **Mid to long term R&D Plans:**

1) With regard to the Stabilized Injectable Formulation – Long-Acting Injectable (SIF-LAI) platform technology, Foresee strive to meet certain unmet medical needs by improving efficacy, mitigating side effects, increasing convenience, or expanding clinical applications, thus reducing the expenditure for new drug development and shortening the time-to-market. Foresee aims to advance the products currently under development to clinical trials in the next one to five years.
2) Regarding the development strategy for the NCE (New Chemical Entity) drug pipeline, the follow-up compounds of MMP-12 inhibitors and ALDH2 activators will continue to be explored for various applications under the same therapeutic mechanism. The focus is on developing innovative drugs targeting high-market potential and unmet medical needs. The MMP-12 inhibitors will be explored for the treatment of chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF). Meanwhile, ALDH2 activator drugs will be investigated for cardiovascular-renal metabolic diseases (CVRM) and central nervous system diseases.

2.2 Pharmaceutical Safety

From research and development, clinical trials, manufacturing, and supply to patient use, Foresee adheres to the highest ethical standards to ensure that the medicines provided to patients are safe, effective, and of high quality. During the clinical trial phase, we maintain ongoing oversight through our Safety Monitoring Team (SMT), which is responsible for continuous monitoring of ongoing clinical trials. The SMT employs a comprehensive internal signal detection mechanism to assess potential safety signals that may impact subject safety.

In addition, we establish a Data and Safety Monitoring Board (DSMB) for each ongoing study. Both the DSMB and SMT convene regular quarterly meetings and may hold ad hoc meetings when necessary. We outsource serious adverse event (SAE) reporting and periodic safety reporting processes to our contract research partners. To date, no clinical trials have been terminated due to any contract research partner's violation of Good Clinical Practice (GCP) guidelines.

Foresee's pharmaceutical products adhere to GMP (Good Manufacturing Practice) and GDP (Good Distribution Practice) regulations throughout the production and packaging processes. Each product package includes a batch number and barcode for product management and traceability, ensuring medication safety. The Company has established the "Procedure for Handling Counterfeit and Prohibited Drugs" and the "Product Recall Procedure." These procedures guide the initiation of product recalls and investigations, with mandatory reporting to regulatory authorities as required. The Company submits the required filings to the Taiwan Ministry of Health and Welfare each year in accordance with the Pharmaceutical

Injury Relief Act. As of the end of 2024, Foresee's CAMCEVI 42 mg has not been subject to any safety-related notifications, recalls, or cGMP violations.

Year	Product Description	Percentage of Stability Assessment Conducted
2022	CAMCEVI 42 mg is used for the treatment of advanced prostate cancer.	100%
2023		100%
2024		100%

2.3 Intellectual Property Management

Foresee's intellectual property management and goals are centered on protecting the company's R&D achievements, strengthening its competitive advantage, and preventing infringement on others' intellectual property rights. Led by the R&D leadership, these strategies are executed in alignment with the Company's business objectives. This ensures comprehensive global patent coverage for each technology and product, and trademark applications are filed in planned sales regions. This approach maintains Foresee's innovation capacity, preserves the value of the Company's technologies, and ensures the sustainable operation of the Company.

Foresee Pharmaceuticals established its "Intellectual Property Management Regulations" in 2015. These guidelines ensure effective control over the internal proposal and external submission processes for patents, trademarks, and other intellectual property rights. The regulations are designed to align with the Company's intellectual property management cycle, ensuring that all related operations are conducted in compliance with established standards.

◻ Patent Management

Global Patent Strategy: Following the internal control system and the intellectual property procedures within the R&D cycle, research outcomes eligible for patent protection are identified. These are submitted as patent proposals, and upon internal evaluation and approval, patent law firms are engaged to file the applications.

Patent Information Sharing: The Company has acquired a legitimate subscription to the SciFinder patent literature database, providing R&D personnel with access to patent searches to reduce the risk of infringement. Educational training sessions are conducted to enhance researchers' understanding of patents, helping them grasp the legal boundaries of product development. This also stimulates creative design thinking, increases sensitivity to patentable concepts, and improves the quality of patents.

Regular Maintenance and Review: A routine review is conducted of granted and pending patents to assess the necessity of continued maintenance and to determine strategies for extending the protection of critical patents.

◻ Trademark Management

Global Brand Strategy: In alignment with the Company's operational goals, global trademark registration applications are submitted proactively.

Regular Maintenance and Review: A routine assessment is conducted on the usage of registered trademarks to evaluate the necessity of continued maintenance.

◻ Trade Secret Management

Confidentiality Management and Awareness: The Company requires all employees to sign a "Service Contract," which clearly defines the ownership of intellectual property, confidentiality clauses, and non-compete agreements. Periodic reminders are provided to employees to ensure they maintain the confidentiality of trade secrets related to their duties.

Access Control Security Management: Employees are granted access card permissions based on their job functions. Non-employees are required to register their identity upon visiting, and are accompanied by company personnel throughout their visit.

Information Security Management: All company computer systems are fortified with multi-layered protection, including complex password verification with mandatory periodic changes, antivirus software on servers and endpoints, network behavior management, malicious website protection, firewall setups, data backup, and encryption. Annual disaster recovery exercises are conducted to ensure information security.

Department-Specific Spaces: The Company provides each department with designated physical and virtual storage spaces to plan and manage independently. Physical spaces are secured by responsible personnel holding the keys, while virtual spaces are granted specific read/write permissions to authorized individuals.

2024 Specific Implementation

1) The Company has been granted 18 global patents this year for SIF and MMP-12 technology, extending intellectual property protection for CAMCEVI® and other developing LHRH products, as well as MMP-12 inhibitor products, until 2039-2040. To date, the Company has acquired a total of 15 patents (equivalent to 136 patents by country), covering 49 countries worldwide, with an additional 11 patents currently under review.
2) Trademarks: A total of 39 trademarks have been registered, covering 16 countries/alliances worldwide, with 5 additional applications currently under review.
3) Participated in the 2024 “TIPS (Grade A) and Corporate Governance Intellectual Property Compliance Training Course” organized by the Institute for Information Industry and InnoX Digital, totaling 26 hours, and obtained the TIPS Self-Evaluator Registration Certificate.
4) Attended the “Essential Patent Courses for R&D Personnel” series organized by the Industrial Technology Research Institute (ITRI), totaling 18 hours.
5) Participated in the “Intellectual Property Management Webinar Series” hosted by ExpoTech, totaling 3 hours.
6) Attended the “Intellectual Property Online Course” organized by the Center for IP and Industry-Academia Innovation, National Yang Ming Chiao Tung University, totaling 3 hours.
7) Participated in the “Patent Portfolio Analysis Webinar” organized by Valuation Master, totaling 2 hours.
8) On November 13, 2024, during the 5th meeting of the 5th session of the Board of Directors, a report was presented on the intellectual property management system and its implementation, ensuring that an annual report is provided to the Board of Directors to align the intellectual property management plan with operational goals.

Number of Patents Acquired

Year	2022	2023	2024
Number of Patents Acquired	5	17	18
Cumulative Effective Patents	50	66	84

2.4 Information Security Management

In this digital age, information security has become an essential component of business operations. To ensure the security and stability of Foresee’s information systems, the Company has established a clear responsibility structure. The Information Technology Department is responsible for formulating and promoting information security policies, ensuring that all operations meet standards and are continuously improved. Concurrently, the Audit Office serves as the supervisory unit for information security oversight, responsible for monitoring the internal execution of information security measures. If deficiencies are found during audits, the audited unit is required to propose relevant improvement plans and concrete actions, with regular follow-ups to track the effectiveness of improvements and reduce internal information security risks.

To ensure the effectiveness of policies and operations, the Information Technology Department reviews the Company's current information security management system, ensuring that the applicability, appropriateness, and effectiveness of related procedures meet the Company's needs. The department also assesses when improvements to related policies and objectives are needed, or if other changes are required. Information security policies should be reviewed immediately in the event of significant changes to ensure their appropriateness and effectiveness. When necessary, relevant units and partners should be informed to facilitate compliance. Through these measures, the Company is committed to establishing a secure and reliable information environment to ensure the confidentiality, integrity, and availability of its information assets.

Information Security Technical Controls

1) Adaptive Access Control is a content-aware access management mechanism with two key features: content awareness and dynamic risk reduction. Content awareness means that the access control system determines which data can be accessed based on the context of the access request, such as the identity of the requester and the type of access device used. Dynamic risk reduction refers to the practice of moderately relaxing access restrictions that might otherwise be blocked, within a certain scope. Currently, network access control (NAC) operates on this framework.
2) Enterprise Network Firewall Deployment involves implementing strict firewall policies to control network access. Externally, this prevents attacks from external hackers and protects the data security and integrity of internal servers. Internally, it provides access logs for employees, which can be crucial for tracking and addressing significant network security issues.
3) Protection Strategy for Microsoft O365 Cloud Email System utilizes the MailGates protection strategy, integrating global anti-spam engines, advanced antivirus engines, dynamic sandbox analysis, malicious URL filtering engines, and email fraud intelligence analysis engines. This multi-layered security approach addresses annoying spam issues and effectively mitigates the risks of ransomware attacks on the enterprise.
4) Information Security Protection for Personal Computers employs Kaspersky antivirus software to effectively safeguard data integrity. Additionally, personal firewalls are used to prevent the theft of personal information online, while access logs are provided for future tracking.

Information Security Incident Notification Procedures

The Company's information security incident notification procedures are as follows. Reporting and handling of security incidents adhere to the guidelines outlined in this procedure.

3. Corporate Governance

Comprehensive corporate governance, including a sound board of directors, stringent internal control systems, and stable financial management, not only helps reduce operational risks but also enhances the Company’s competitiveness and creates corporate value. Foresee Pharmaceuticals is committed to building a corporate culture based on integrity and responsibility, strictly adhering to all regulations, and implementing honest business practices. Through a comprehensive corporate governance framework, Foresee ensures the sound development of the Company's operations, protects the rights and interests of investors and other stakeholders, achieves sustainable corporate growth, and creates long-term value for all stakeholders.

On May 13, 2022, Foresee’s Board of Directors appointed the Company’s Chief Financial Officer, Max Chan, as the Corporate Governance Officer to assist in the operations of the Board and regularly report to the Board. In the 10th Annual Corporate Governance Evaluation for 2023, our company was ranked in the 6-20% range. This reflects our effective performance across various aspects of corporate governance. Moving forward, Foresee will continue to enhance the overall effectiveness of corporate governance practices, further strengthening stakeholder trust in Foresee Pharmaceuticals.

In alignment with the Financial Supervisory Commission's “Corporate Governance 3.0 - Sustainable Development Roadmap,” the Company has implemented directors and officers (D&O) liability insurance to ensure that directors can effectively fulfill their duties while balancing their responsibilities. Since 2016, the Company has provided D&O liability insurance for all directors and officers. The Company also reports key details such as the insurance coverage amount, scope of coverage, and liability limits to the Board of Directors.

3.1 Board of Directors

The Board of Directors is the highest governing body and the center of major business decisions within the Company. Its responsibilities include providing strategic guidance, overseeing management, and being accountable to the Company and its shareholders. The Board ensures that the Company exercises its powers in compliance with laws, the Company's articles of incorporation, or shareholder resolutions, and guides the implementation and arrangement of corporate governance practices. The Company has established the Board of Directors' meeting rules and related regulations in accordance with the “Regulations Governing Procedure for Board of Directors Meetings of Public Companies” and the provisions of Article 192 of the Company Act. Board elections are conducted following the Company's “Board Election Rules,” with shareholders electing from the list of candidates. Directors serve a 3-year term and may be re-elected. By law, the Board must meet at least once per quarter. In 2024, the Board held a total of 10 meetings, with an average attendance rate of 95.56% among all directors.

3.1.1 Diversity and Independence of the Board of Directors

Based on the Company’s “Corporate Governance Best-Practice Principles”, elected Board of Directors shall be determined by taking diversity into consideration. Apart from ensuring that directors who also serve as company executives do not exceed one-third of the total board seats, the company should establish appropriate diversity policies based on the company's business operations, operating dynamics, and development needs. The specific management goals are to have at least one-third of the board members with a background in the biotech industry, at least 1 member with financial and accounting expertise, at least 1 member with legal expertise, and at least 1 female director.

At present, the Board of Directors has 9 members, including 4 Independent Directors. 1 female member (11%), who is also an independent director and 8 male members (89%). There are only 2 board members with a close familial relationship (within the second degree of kinship), which does not exceed half of the total board seats, ensuring the independence of the board. Among the board members, 9 members have professional background in the biotechnology industry, 3 members have financial and accounting expertise and 1 member has legal expertise. The composition of the Company's Board of Directors includes members of different genders and possesses the necessary knowledge, skills, and qualifications for their roles. The current situation aligns with the Company’s goals, demonstrating a strong commitment to board member diversity and independence.

3.1.2 Board Performance Evaluation and Continuing Education

The Company has established the rules and procedures for evaluating the performance of the Board of Directors and it has been approved by the Board in 2020. The internal performance evaluation will be conducted annually, and evaluation will be conducted by external professional independent institutions or external team of experts and scholars once every three years. We believe this will enhance the quality of the Board's decision-making, strengthen the Company's internal controls and relationship management, and promote the ongoing education and professional development of the directors. Through this system, we aim to further elevate the level of corporate governance and achieve the Company's sustainability goals.

In 2024, the average self-assessment score for the Board of Directors was 4.8 out of 5, while the average self-assessment score for individual directors was 4.84 out of 5. Several board members provided positive feedback regarding the Board of Directors, highlighting that the overall efficiency and professionalism of the Board's operations are excellent. Directors frequently offer professional advice based on their extensive experience and effectively assess and oversee the Company's operations. The Board operates smoothly and maintains good communication with the management team.

Board Performance Evaluation			
	2022	2023	2024
Self-Assessment (Questionnaire)	4.82 (Out of 5)	4.82 (Out of 5)	4.8 (Out of 5)
External Assessment	4.77 (Out of 5)	N/A	N/A

In 2022, the external evaluation of the Board of Directors' performance was conducted by the Taiwan Institute of Ethical Business. The evaluation was completed on March 8, 2023, and the results were reported to the Board of Directors on March 23, 2023. The summary of the recommendations from the evaluation is as follows:

- It is recommended that future Board compositions consider factors such as gender and age to promote greater diversity. This could introduce different perspectives and enhance risk assessment considerations.
- Given that the Chairman also serves as the CEO, it is advised that the Company add an independent director seat to fulfill regulatory compliance requirements.
- To facilitate better review of past decision-making experiences, it is suggested that key discussion points from meetings be summarized in the minutes. This will aid in applying past experiences to future decision-making.
- It is recommended that, in alignment with operational directions and industry trends, the Company arrange courses for relevant domestic and international industry trend or foreign regulatory system trends. This will enhance directors' understanding of the industry and improve the Board's grasp of competitive conditions and industry trends.

The Company addressed the recommendations from the above evaluation results and will continue to implement the following improvement measures:

1) On June 1, 2023, Foresee appointed an additional independent director with a legal background to comply with regulations and enhance board diversity and independence.
2) The Company arranged training courses for directors annually. All current Board members participated in 6 hours of sustainability-related courses in corporate governance and taxation in 2024, with a total of 63 hours of continuing education for the entire Board during the year.

2024 Board of Directors Training Courses

Date	Organizer	Course
2024/4/18	Institute of Financial Law and Crime Prevention	Anti-Money Laundering, Counter-Terrorism Financing Practices, and Insider Trading Prevention Awareness
2024/5/16	Taiwan Securities Association	Financial Consumer Protection Act and Principles of Fair Customer Treatment
2024/9/27	Securities and Futures Institute	Cybersecurity Management Act and Case Studies of Sanctions by the Three Financial Regulators
2024/10/17	Taiwan Securities Association	Trends in Sustainable Finance and the Taskforce on Nature-related Financial Disclosures Framework
2024/10/28	Taipei Foundation of Finance	Corporate Governance: Development Trends in the Generative AI Industry
2024/12/12	Securities and Futures Institute	Overseas Investment and M&A: Practical Analysis and Key Issues for Enterprises
2024/12/20	Securities and Futures Institute	Tax Governance Strategies for Building Supply Chains Across Geopolitical Blocs

3.1.3 Compensation of Directors and Supervisors

Independent directors of the Company receive fixed compensation, while other directors, aside from receiving attendance fees for participating in Board meetings, do not receive any additional compensation. In accordance with article 28 of the Company's Articles of Incorporation, if the company makes a profit during the year, 1% to 10% should be allocated as the employee compensation, while no more than 2% should be allocated as directors' compensation. The allocation of compensation is decided by the Board of Directors and reported to the shareholders' meeting. In 2024, the Company did not distribute any compensation to directors or employees.

Supervisor salaries and performance bonuses are determined based on industry standards, taking into account factors such as the individual's time investment, responsibilities, performance in other positions, and recent compensation levels for similar positions within the Company. Additionally, considerations include the supervisor's achievement of targets, operational management abilities, and other special contributions (e.g., progress in product development, research patents, drug approvals, and product licensing). After a comprehensive evaluation, compensation is set at a reasonable level. Individual performance and the Company's operational performance are assessed based on the achievement of short- and long-term business objectives, financial conditions, and the alignment of performance with future risks. Compensation recommendations are made by the Compensation Committee and approved by the Board of Directors. Moving forward, the Company's ESG performance will be progressively linked to the compensation of directors and supervisors.

3.1.4 Board Communication and Conflict of Interest

Foresee has established effective two-way communication to implement good corporate governance. In addition to discussing and expressing differing opinions during regular Board meetings, directors also engage in discussions prior to meetings or use other communication channels to exchange views Directors may present their opinions and respond to inquiries on matters in which they or their represented entities have a conflict of interest. However, they must abstain from participating in discussions and voting on such matters, and are not allowed to proxy their voting rights for other directors.

Communication of Material Information

To enhance the transparency of the Company's operational information, we disclose significant event information in real-time through the Market Observation Post System, ensuring the protection of stakeholder interests. Foresee's procedure for disclosing significant information follows the regulations set forth by the "Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities." After submission by the applicant, the information is reviewed by the relevant supervisors and spokesperson. It is then approved and executed by the Corporate Governance Officer or the Vice President of Preclinical Development and R&D Site Manager, as authorized by the Chairman. In 2024, the number of material information releases approved by the Board of Directors was as follows:

Stakeholder Matters	Financial Matters	HR-Related Matters	Other
5	9	5	3

Communication between Independent Directors, Internal Audit Supervisors, and Accountants

- CPAs regularly hold quarterly Audit Committee meetings to discuss the scope of audit or review of the Company's financial statements, the results of the audit or review, and updates on relevant regulations.
- The internal audit unit submits the previous month's audit report to the Independent Directors for review via email on a monthly basis. Additionally, the Internal Audit Supervisor presents the audit business report at the quarterly Audit Committee meetings.
- The Company holds at least one separate meeting annually with Independent Directors, CPAs, and the Internal Audit Supervisor.
- Additionally, Independent Directors may contact the Internal Audit Supervisor and CPAs via email or phone as needed.
- Separate Communications Between Independent Directors with CPAs and the Internal Audit Supervisor in 2024:

2024/12/18 Meeting Attendance：Four Independent Directors, CPAs, and Internal Audit Supervisor	
Communicated Matters	**Communication Results**
In 2024, discussions between the CPAs and the governance unit focused on audit quality indicators. The topics covered included 5 major aspects: professionalism, independence, quality control, supervision, and innovation capabilities.	All attendees understood the information presented.
Understand the most challenging matters encountered by the auditor during the audit or review process.	All attendees understood the information presented.
Understanding how CPAs communicate and collaborate with management during the audit or review process.	Communication remained effective throughout the year. Apart from increased interactions resulting from the change in accounting manager, no audit restrictions were encountered.
Understanding the auditor’s audit or review procedures performed on subsidiaries.	Except for the time zone differences with subsidiaries, overall cooperation and data accessibility were satisfactory.

Implementation of Conflict of Interest Provisions

Following the retirement of the former CEO on January 1, 2021, the Chairman, considering the overall operational status of the Company, has continued to serve as the acting General Manager. This role encompasses overall management of Foresee’s operations in Taiwan, the United States, Canada, and Australia. Responsibilities include overseeing product line progress, manufacturing, regulatory affairs, research and development, and information systems. Additionally, the Chairman is involved in significant decisions including formulating the Company's future strategies, research and development projects, investments, and mergers and acquisitions.

The Chairman, who also serves as the CEO, ensures that all matters related to Board decision-making are thoroughly communicated and discussed with Board members. Additionally, more than half of the Board members do not hold positions as employees or supervisors within the Company. To strengthen the supervisory role of the Board of Directors, the Company appointed an additional independent director at the 2023 Shareholders' Meeting, increasing the number of independent directors to 4 in compliance with relevant regulations. We are also continuing to search for a suitable candidate to fill the CEO position.

In 2024, there were 19 proposals involving four independent director and three other directors. All involved parties duly recused themselves and did not participate in the discussions or voting on these matters.

3.1.5 Functional Committees

To enhance the overall function of the Board of Directors, improve audit supervision, and strengthen management mechanisms, Foresee Pharmaceuticals has established 2 functional committees under the Board: the Audit Committee and the Compensation Committee. These committees operate independently in accordance with regulations and are accountable to the Board. Proposals put forth by the committees are submitted to the Board for resolution.

3.1.5.1 Audit Committee

The Company's Audit Committee is composed of four Independent Directors. Upon appointment by the Board of Directors, Independent Director Mr. Hank Lai, Independent Director Mr. Frank Wen-Chi Lee, Independent Director Ms. Fu-Shiow Yin, and Independent Director Mr. Ben Liu were elected as members of the second Audit Committee. Their term of office is from June 24, 2024, to June 23, 2027. Mr. Hank Lai was elected as the convener of the Audit Committee.

The primary responsibilities of the Audit Committee are to assist the Board of Directors in overseeing the quality and integrity of the company's accounting, auditing, financial reporting processes, and financial controls. The Audit Committee operates with the primary objectives of overseeing the accurate presentation of the Company's financial statements, the selection and performance of certified public accountants, the effectiveness of internal controls, compliance with relevant laws and regulations, and the management of existing or potential risks to the Company. Foresee's Audit Committee, consisting of 4 independent directors, is chaired by Mr. Hank Lai. In 2024, the committee held a total of 9 meetings, with an average attendance rate of 100%.

3.1.5.2 Compensation Committee

The Company's fourth Compensation Committee is composed of four Independent Directors appointed by the Board of Directors. Their term of office is from July 30, 2024, to June 23, 2027. Ms. Fu-Shiow Yin was elected as the convener of the Committee.

The Compensation Committee is responsible for assisting the Board in reviewing the Company's overall compensation policies, systems, standards, and structures, as well as the performance evaluation criteria and goals for Directors and managerial officers. Based on the performance results, the Committee determines corresponding compensation packages. It also periodically reviews the organizational charter and provides recommendations for amendments. In 2024, the Compensation Committee convened 3 meetings, with an average attendance rate of 100%.

3.1.6 Internal Audit

The Company's internal Audit Office is an independent unit reporting to the Board of Directors. It assists the Board and management in identifying and reviewing deficiencies in internal controls and measuring operational efficiency. The internal Audit Office regularly reports audit activities to the independent directors, and attends Board meetings on a quarterly basis. Additionally, the internal audit holds an annual separate meeting with the independent directors and CPAs to ensure that internal controls are effectively implemented and to provide a basis for reviewing and amending the internal control systems.

The Company ensures continuous monitoring of its operations through annual risk assessments conducted by auditors. This approach effectively implements various operational systems and establishes a robust risk management mechanism. In 2024, the Audit Office conducted with 45 audits, achieving a 100% compliance rate. No major non-compliance issues or audit deficiencies were found that would require the issuance of improvement tracking reports.



3.2 Risk Management

Foresee has established internal control systems, relevant operating procedures, and information security risk management frameworks in accordance with the law. We conduct various risk management and assessments, formulate and execute plans, and continuously monitor and improve on any outstanding issues to manage potential or existing risk issues.

Category	Description	Management Strategy
Corporate Governance	New Drug R&D	1) Implement a global patent protection strategy to secure product competitive advantages in key sales markets. 2) Ensure compliance with GxP-related regulations and guidelines, such as GMP (Pharmaceutical Good Manufacturing Practice) and GCP (Good Clinical Practice), for product and service marketing and labeling. 3) Establish long-term partnerships with third-party collaborators to deepen cooperation and reduce risk variables. 4) Plan for technology transfer and establish secondary suppliers to enhance production capacity, diversify risks, and manage supply and demand effectively. 5) Create a dedicated stakeholder section on the Company website, providing contact information for competent authorities, investors, drug development partners, and suppliers.
	Regulatory Compliance	1) The Company has established “Corporate Governance Best-Practice Principles,” “Procedures for Ethical Management and Guidelines for Conduct,” “Code of Ethical Conduct,” and “Employee Code of Conduct.” Through internal control mechanisms, accounting systems, and contract signing, the Company ensures legal compliance and integrity in its business operations. Additionally, internal audit mechanisms and the Company's complaint system are in place to prevent regulatory violations or dishonest business activities. 2) The “Procedures for Ethical Management and Guidelines for Conduct” explicitly outlines a whistle-blowing system. The Company provides a dedicated hotline and email address on its website for complaints and whistle-blowing, which are handled by designated personnel in the audit department. The identity of the whistle-blower and the content of the report are kept confidential. Employees suspecting any violation of conduct can report it through the employee communication hotline or the HR email. 3) The Company collaborates with law firms and professional consultants to ensure regulatory compliance and take necessary measures. 4) Plans are in place to establish a dedicated unit responsible for promoting and supervising legal compliance and corporate ethical management.
	Information Security Incident	1) Establish an information security team and engage external consultants to be responsible for information security policies, assist in planning and executing information security operations, and promote and enforce information security policies. 2) The Audit Office serves as the supervisory unit for information security oversight, responsible for monitoring the internal execution of information security measures. If deficiencies are found during audits, the audited unit is required to propose relevant improvement plans and concrete actions, with regular follow-ups to track the effectiveness of improvements and reduce internal information security risks. 3) The information security team will hold at least one meeting annually to review the Company‘s current information security management system, ensuring that the applicability, appropriateness, and effectiveness of related procedures meet the Company's needs. 4) Conduct disaster recovery exercises annually to ensure information security and prevent potential impacts or disruptions to the Company.
	Information Disclosure Transparency	1) A dedicated stakeholder section has been set up on the Company’s website, providing relevant contact information to prevent misunderstandings with stakeholders that could lead to operational or legal risks. 2) Information that may affect shareholders and stakeholders‘ decisions is timely and appropriately disclosed through annual reports, the Market Observation Post System, and occasional participation in investor meetings organized by brokerage firms.
Environmental	Toxic Substances and Waste	The Company complies with environmental regulations regarding the handling and management of chemical raw materials and toxic chemicals used in research and development. We regularly report to the competent authorities and engage qualified vendors for the periodic disposal of different types of waste. To date, there have been no records of violations of environmental regulations.
Social	Accidents/Disasters	Regularly participate in disaster preparedness drills conducted in the industry park where the Company is located, as well as in chemical substance management seminars organized by competent authorities, to develop employees' emergency response and self-safety management skills.
	Human Rights	The Company refers to international human rights conventions and related regulations, such as the “Universal Declaration of Human Rights” and “International Labour Organization (ILO) Conventions,” to develop policies including “Leave and Overtime Management Regulations,” “Work Practices,” and “Measures for Preventing and Addressing Sexual Harassment in the Workplace, Complaints, and Disciplinary Actions.” We also comply with relevant labor laws to maintain a sound management system.
	Personnel Management	Foresee is committed to establishing a fair and equitable compensation system, adhering to relevant labor regulations and market standards to ensure that employees receive the appropriate remuneration. The goal is to attract top talent and enhance employee motivation through a competitive and industry-leading salary policy, which balances effective talent retention and incentive rewards. Under this compensation system, we ensure that no differentiation is made based on factors such as gender, nationality, race, religion, political stance, or marital status, guaranteeing fair and just treatment for all employees.

3.3 Regulatory Compliance

Foresee Pharmaceuticals' regulatory compliance framework consists of legal tracking, the development and implementation of internal regulations, compliance training, and the establishment of accessible reporting channels. The Company has established a regulatory department with 5 professionals, including legal experts and internal auditors, to establish the "Corporate Governance Best Practice Principles," "Procedures for Ethical Management and Guidelines for Conduct," along with various management regulations and internal control mechanism in compliance with the Labor Standards Act, Securities and Exchange Acts, and industry-specific laws such as the Pharmaceutical Affairs Act, Controlled Drugs Act, Toxic and Concerned Chemical Substances Control Act, and Permit Management Regulations for Public and Private Waste Clearance and Disposal Organizations. These are implemented across all departments to ensure regulatory compliance, with internal audits conducted regularly and reports submitted to the Board of Directors.

In 2024, the Company did not receive any reports of violations related to financial or accounting matters, and there were no significant legal infractions (fines exceeding NT$100,000).

3.4 Business Performance

On the path to sustainability, operational performance plays a crucial role. For Foresee Pharmaceuticals, stable financial performance is not only the foundation for sustainable development but also a key avenue for giving back to investors, society, and nurturing local talent. The Company focuses on innovative R&D, concentrating on both short-term sustainable revenue and long-term high-value operational models to balance the Company's financial condition. We are committed to attracting international top talent and engaging in strategic partnerships with global pharmaceutical partners. The goal is to enhance Foresee's global intellectual property portfolio and become a globally competitive, internationally renowned new drug research and development company. We aim to continuously reward the support and expectations of stakeholders through these efforts, establishing a solid foundation for sustainable development.

Short-term Goals	1) Prepare for the commercial launch for CAMCEVI® 42 mg (6-month LAI formulation) in the EU and Canada. 2) Assist GeneScience Pharmaceuticals, Foresee's licensing partner for China, in responding to the regulatory review of the MAA of leuprolide injectable emulsion (i.e., CAMCEVI® 42 mg 6-month LAI formulation) for patients with advanced prostate cancer. 3) Receive review comments from the U.S. FDA for CAMCEVI® 21 mg (3-month LAI formulation), assist Accord Healthcare, Foresee's licensing partner for EU, in responding to the regulatory review of the MAA of CAMCEVI® 21 mg, and prepare for marketing authorization submissions for other key markets. 4) Continue the global out-licensing discussion of SIF or NCE related program.
Mid- to Long-term Goals	1) Products under development based on the SIF-LAI long-acting and stable injectable platform technology are expected to successively enter clinical trials over the next one to five years. 2) For the development strategy of the innovative small molecule new chemical entity (NCE) product line, the focus is on conducting and completing proof-of-concept clinical trials, while initiating discussions on cross-border collaborations in line with the clinical development timeline.

Resources Invested in the Current Year	1) The six-month formulation of CAMCEVI has received marketing authorization in Israel and the United Kingdom. 2) A New Drug Application (NDA) for the three-month formulation has been submitted to the U.S. FDA.
Evaluation Mechanisms/Results	1) The Company sets annual operational goals and budgets, which are approved after discussion by the Board of Directors. Progress toward these goals is reported to the Board on a quarterly basis, and the annual operational performance is also evaluated by the Board. 2) The senior management team holds operational meetings every four months to review the execution status. 3) In 2024, the Company's operational performance achieved the “Exceed Expectation” level. 4) In 2024, the net sales revenue was NT$449,493 thousand.

Unit: in thousands of New Taiwan Dollars

Item	2022	2023	2024
Revenue (A)	$301,506	$195,038	$449,493
Operating Costs (B)	$25,539	$81,066	$178,888
Employee Compensation and Benefits (C)	$134,434	$120,032	$105,839
Payments to Investors (D)	$278	$2,395	$6,420
Payments to Government (E)	$29,903	$40,312	$36,640
Community Investment (F)	$231	$284	$104
Retained Economic Value (A-B-C-D-E-F)	$111,121	- $49,051	$121,602

Data Source: Standalone financial statements of the Company

4. Environmental Sustainability

4.1 Climate-Related Financial Disclosures

Due to the increasing impact of extreme weather caused by global warming and recent issues related to energy and climate change, Foresee is addressing the effects of climate change on its operations. Starting in 2023, the Company follows the framework recommended by the Task Force on Climate-related Financial Disclosures (TCFD), which includes Governance, Strategy, Risk Management, and Metrics and Targets. The Sustainable Development Group identifies climate-related risks and opportunities, formulates corresponding strategies, and reports to the Board of Directors annually. The Board monitors the effectiveness of these strategies.

TCFD Risk Management Process

Step1
- The Sustainable Development Group completes the collection of climate risk-related data.
- Scope of disclosures and climate risk assessment.

Step2
- Develop a list of climate risk and opportunity items.

step3
- The Sustainable Development Group conducts an impact analysis of climate risks and opportunities on operations.
- Determine significant risk items.

step4
- Develop response strategies and set goals for significant risk items.

step5
- Each year, the Sustainable Development Group also conducts rolling reviews to assess the effectiveness of executed strategies and goal attainment.

4.1.1 Climate Change Management Framework

Governance	To fulfill corporate social responsibility, the Company has designated the Sustainable Development Group to oversee corporate governance, environmental protection, climate change, and labor-related issues. The Group holds regular ESG meetings and reports the execution performance and necessary improvement recommendations to senior management. Annually, the Group presents the previous year's results and this year's work plan to the Board of Directors, incorporating their feedback for revisions. Additionally, given the importance of environmental issues and the increasing international focus on climate change, the Group includes climate change risk-related topics and management goals in their agenda.
Strategy	The Company references the climate-related scenario analysis recommended by the Task Force on Climate-related Financial Disclosures (TCFD). We use both quantitative and qualitative analyses to adopt appropriate measures, integrating the impacts of climate-related risks and opportunities into the Company's strategies and planning. The Company references the 2°C scenario (2DS) and discusses the definitions for short-term, medium-term, and long-term intervals in Sustainable Development Group meetings. "1-3 years" is set as the short term, "3-5 years" as the medium term, and "6-10 years" as the long term, and conduct climate risk and opportunity assessments accordingly. Climate risk types include two main categories: transition risks and physical risks. The risks are further divided into policy and regulatory, technology, market, and reputation risks, as well as immediate and long-term risks. Opportunities are classified into five main categories: resource efficiency, energy sources, products and services, markets, and organizational resilience.
Risk Management	1) The Sustainable Development Group completes risk identification during TCFD discussion meetings, evaluating how climate change factors might impact the Company's operational transition and physical risks and opportunities based on inputs from various units. 2) Identified potential transition and physical risks (a total of 6) and potential opportunities (a total of 3) that may arise due to climate change factors affecting company operations.
Metrics and Targets	1) To minimize the impact of operations on the surrounding environment, Foresee focuses on all environmental indicators, including energy conservation and carbon reduction, water resource efficiency, pollution control, and hazardous substance management, to achieve sustainability goals. 1) Complete greenhouse gas inventory and verification by 2028.

4.1.2 Climate Risk and Opportunity

Risk Issues	Level	Impact Duration	Opportunity Issues	Level	Impact Duration
R1 Increase Greenhouse Gas Emission Pricing	High	Short Term, Medium Term	O1 Adopt More Efficient Transportation Methods	High	Short Term, Medium Term
R2 Requirements for Existing Products and Services	Low	Short Term	O2 Utilize More Efficient Production and Distribution Processes	Low	Short Term
R3 Facing Litigation Risks	High	Short Term, Medium Term	O3 Recycling and Reuse	Low	Short Term, Medium Term
R4 Substitute Existing Products and Services with Low-Carbon Alternatives	Low	Medium Term	O4 Transition to More Efficient Production Processes	High	Short Term, Medium Term, Long Term
R5 Investment Failure in New Technologies	Low	Short Term	O5 Reduce Water Usage and Consumption	Low	Medium Term
R6 Costs of Transitioning to Low-Carbon Technologies	Low	Short Term	O6 Utilize Low-Carbon Energy	Low	Medium Term, Long Term
R7 Changes in Customer Behavior	Low	Short Term, Medium Term	O7 Adopt Incentive-Based Policies	Low	Medium Term, Long Term
R8 Market Risks	Low	Medium Term, Long Term	O8 Implement New Technologies	High	Medium Term, Long Term
R9 Rising Raw Material Costs	High	Short Term, Medium Term	O9 Participate in Carbon Trading Markets	Low	Medium Term, Long Term
R10 Shifts in Consumer Preferences - Industry Stigmatization	Low	Short Term, Medium Term			
R11 Increased Negative Feedback from Stakeholders	High	Short Term			
R12 Increased Severity of Extreme Weather Events, Such as Typhoons and Water Supply Issues	High	Short Term, Medium Term, Long Term			
R13 Changes in Precipitation (Water) Patterns and Extreme Variations in Climate Patterns	Low	Short Term, Medium Term, Long Term			
R14 Increase in Average Temperature	High	Medium Term, Long Term			
R15 Rising Sea Levels	Low	Long Term			

4.1.3 Climate Risk Identification

Type	Issue	Climate-Related Risks	Potential Financial Risks	Risk Mitigation Strategies
Transition Risks	Policies and regulations	1) Carbon fees and carbon taxes 2) Introduction of new regulations	1) Increased 3% ~ 5% operational costs (e.g., compliance costs and higher insurance premiums) 2) Cost increases due to fines and legal judgments	✓ Improving resource efficiency lowers operational costs and supports energy-saving and carbon-reduction goals. ✓ Encourage employees to use public transport or electric vehicles and support office greenery to reduce carbon emissions. ✓ Offices use energy-efficient LED lighting and implement improvements in air conditioning temperature and operating hours to reduce electricity consumption. ✓ Conduct greenhouse gas inventory to analyze emissions and set reduction targets.
	Market	Rising raw material costs	5% ~ 10 ~ Increased operating costs, reduced 3% ~ 8% profits	✓ Regularly communicate with suppliers to monitor material supply and production schedules, and assess potential partners to strategically diversify supply chain risks. ✓ Utilize technology transfer to establish local/regional supply chains, reducing material transport costs and product carbon footprint. ✓ Continuously optimize production processes to reduce raw material consumption.
	Reputation	Increasing stakeholder concerns and negative feedback	Decline in demand for products/services	✓ Complete a group-wide greenhouse gas inventory to develop reduction strategies, ensure compliance with regulations for laboratory waste management and disposal, enhance communication with stakeholders, and build a strong sustainability image for the Company.
Physical Risks	Short Term	Increased severity of extreme weather events, such as typhoons and flooding Issues	1) Reduced or disrupted production capacity (e.g., shutdowns, transportation difficulties, supply chain interruptions) 2) Impact on workforce management and planning (e.g., health, safety, absenteeism)	✓ Establish a product safety stock. ✓ Expand global drug registrations to mitigate regional climate risks. ✓ Enhance supply chain stability through technology transfer and evaluation of potential backup suppliers. ✓ Install UPS systems to reduce operational disruptions and losses caused by power outages from extreme weather events. ✓ Join regional joint prevention organizations and participate in disaster drills to enhance internal and external response and support capabilities.
	Long Term	1) Increased likelihood of extreme weather events 2) Increase in average temperature	1) Increased asset insurance premiums raising operational costs 2) Increased water and electricity usage	✓ To address the need for cold chain transportation, establish local/regional supply chains to reduce carbon emissions and product carbon footprint during shipping. ✓ Prioritize procurement of energy-efficient equipment to reduce direct carbon emissions.
Opportunities	Resource Efficiency	Adopt more efficient transportation methods	1) Reduce operating costs 2) Increase production capacity to boost revenue	✓ Continuously develop innovative products that can be transported under room temperature conditions, offering higher resource efficiency compared to cold chain transport. ✓ Focus on the sustainability of cold chain logistics as a criterion for evaluating suppliers.
		Utilize more efficient production and distribution processes		✓ Continuously optimize product processes to enhance resource efficiency. ✓ Establish local/regional supply chains to improve production and distribution processes, reducing the product carbon footprint.
		Implement new technologies		✓ Continue investing in R&D and optimize product processes to reduce energy consumption.

4.2 Energy and Water Resource Management

Foresee Pharmaceuticals is not classified as a high carbon-intensive industry, so related regulations currently have no significant immediate impact on the Company's overall operations. We have gradually implemented greenhouse gas inventories, established management strategies and carbon reduction targets. The Company's greenhouse gas emissions primarily come from energy use during operations, direct emissions (Scope 1) are primarily from refrigerant leakage. Indirect emissions (Scope 2) are primarily from purchased electricity (non-renewable energy). The energy consumption and greenhouse gas emissions over the past two years are summarized in the table below.

In 2024, energy intensity and carbon emission intensity declined by approximately 50% compared to the previous year. Nevertheless, per capita emissions increased relative to 2023. To support our carbon reduction goals, we aim to reduce per capita emissions by 10% by 2028 compared to 2023. Key initiatives include the procurement of energy-efficient equipment with certified energy-saving labels and high-performance specifications—such as air conditioning systems, IT hardware, LED lighting, and green building materials—along with regular maintenance and upgrades to sustain optimal energy efficiency. Through the SIF-LAI technology platform, we are developing long-acting pharmaceuticals aimed at reducing medication frequency and the need for patient visits. Furthermore, the adoption of remote and home-based work models contributes to lowering carbon emissions from transportation. We are also continuously improving and optimizing our manufacturing processes to enhance the energy efficiency of our products.

Energy Usage Overview	2022	2023	2024
Total Electricity Consumption (kWh)	247,118	465,448	519,200
Total Energy Consumption (GJ)	889.626	1,675.613	1,869.120
Annual Revenue (NT$ million)	301.506	195.038	449. 493
Energy Intensity (GJ/NT$ million)	2.951	8.591	4.158

Greenhouse Gas Emissions (CO2e)	2022	2023	2024
Scope 1 (Note)	1.886	1.886	2.163
Scope 2 (Note)	122.324	229.931	246.101
Total Greenhouse Gas Emissions (Co2e Tons)	124.210	231.817	248.264
Annual Revenue (NT$ million)	301.506	195.038	449.493
Per Capita Emissions	0.412	1.189	0.552
Carbon Emission Intensity	3.357	5.795	5.911

Note: Greenhouse gas inventory follows the Ministry of Environment’s “Guidelines for Greenhouse Gas Emission Measuring” and has not undergone third-party verification. Scope 1 includes fugitive emissions; Scope 2 covers purchased electricity.

Note: Electricity emission factors are based on the Ministry of Economic Affairs’ annual coefficients, with 2022/2023/2024 factors at 0.495/0.494/0.474 kg CO2e/kWh.

Note: CO2e emission factors are derived from the Global Warming Potential (GWP) ratios, primarily based on the Ministry of Environment’s “Greenhouse Gas Emission Coefficients Management Table 6.0.4 Edition.”

In terms of water resource management, the Company has set 2023 as the baseline year, with a target of reducing per capita water consumption by 0.5% every three years. This initiative is part of our response to water scarcity issues and is implemented through internal water-saving practices. In 2024, per capita water consumption decreased by approximately 10% compared to 2023.

Water Resource Usage	2022	2023	2024
Water Consumption (cubic meters)	1,060	718.69	680
Water Intensity	3.52	3.68	1.62
Per Capita Water Consumption	28.65	17.97	16.19

4.3 Laboratory Waste Management

Foresee's R&D Site, located in the National Biotechnology Research Park, is primarily responsible for early-stage fundamental research and does not have facilities that discharge large amounts of wastewater, waste, or greenhouse gases. The operation and management of chemical raw materials and toxic substances used in R&D, as well as the laboratory-generated waste, comply with government environmental regulations. Waste is entrusted to qualified treatment contractors for regular collection and disposal according to the type of waste, ensuring regulatory compliance, traceability, and environmentally responsible management.

Short-term Goals	1) Continuously monitor and manage waste generation. 2) Develop a “Waste Management Procedure Manual.”
Mid- to Long-term Goals	1) Implement the “Waste Management Procedure Manual” for effective waste classification, collection, management, and disposal. 2) Use ISO 14001 standards as environmental assessment criteria to achieve sustainability goals.
Resources Invested in the Current Year	We have entered into agreements with government-approved public and private entities for the removal and treatment of laboratory waste to ensure effective waste management and accurate documentation of total waste volumes. In 2024, the investment related to laboratory waste management amounted to approximately NT$236,000.
Evaluation Mechanisms/Results	To date, there have been no violations of environmental regulations. The Company will continue to monitor and track waste treatment weights moving forward.

Hazardous Waste Types	2022		2023		2024	
	Recycled	Incinerated	Recycled	Incinerated	Recycled	Incinerated
D-2302	-	0.99	-	1.92	-	1.62
C-0599	-	-	-	0.43	-	0.50
Total	-	0.99	-	2.35	-	2.12

Note: D-2302 (Waste solution containing organic solvents)

Note: C-0599 (Mixed infectious waste)

Note: As general waste and domestic wastewater are managed by the Biotech Park administration, they are excluded from the statistical data.

4.4 Sustainable Supply Chain Management

The company’s industrial value chain spans the upstream, midstream, and downstream segments, encompassing preclinical and clinical trial centers, active pharmaceutical ingredient (API) and excipient suppliers, pharmaceutical CDMO manufacturers, pharmaceutical companies, logistics and warehousing, and marketing channels both domestically and internationally. Foresee employs a high-efficiency drug development model that begins with drug screening. Before entering clinical trials, “Proof of Concept” studies are conducted. We then work with regulatory agencies such as the US FDA (Food and Drug Administration), South Korea's MFDS (Ministry of Food and Drug Safety), and China's NMPA (National Medical Products Administration). The aim to establish reasonable and expedited clinical and regulatory pathways through these negotiations, thereby reducing significant time and resources required to move from exploration to a candidate drug, while also mitigating development risks. Concurrently, we have established long-term, close partnerships with upstream and downstream collaborators (including licensing and co-marketing partners) to maximize the value and effectiveness of our research and development outcomes.

Foresee is committed to providing patients with the highest quality and safest products. We have established a stable, secure, and traceable supply chain, covering production scheduling, quality control, drug transportation, and cost considerations. The Company adheres to quality management policies and relevant legal and external GMP/GDP standards throughout the product lifecycle. We strengthen the overall supply chain's safety and stability to create a high-quality, safe, and reliable drug supply chain.

As an international new drug development company, Foresee values having reliable and resilient suppliers. We consider suppliers as essential partners for ongoing growth. The Company evaluates suppliers with annual transaction amounts of $500,000 or more or those with eight or more transactions per year, focusing on quality, delivery timelines, cooperation, and pricing. Evaluations are conducted annually, led by the procurement team in collaboration with relevant departments, using the "Annual Vendor Evaluation Form."

Short-term Goals	1) Optimize the "Pharmaceutical Supplier Evaluation Procedure Manual" and the "Quality Manual." 2) By 2026, Foresee plans to complete the evaluation of suppliers on sustainability aspects, including environmental management, social responsibility, labor rights, and governance, to ensure they meet the Company's sustainability requirements. 3) Meet market supply demands promptly when demand increases.
Mid- to Long-term Goals	1) Supply Chain Management: Ensure sustainable sourcing of raw materials in the supply chain, increase supply flexibility, maintain stable quality, and plan for potential market demand. Require suppliers to adhere to social responsibility and environmental impact reduction. 2) Assess the demand for CAMCIVI 42 mg in Europe, Canada, and Taiwan, and plan production lines, raw materials, and market launch preparations.
Resources Invested in the Current Year	1) Regular weekly or bi-weekly meetings with active pharmaceutical ingredient suppliers and CDMO manufacturers to stay updated on production schedules and actual manufacturing processes. 2) Conducted 10 site visits to raw material suppliers and contract manufacturing organizations, and approximately 8 visits to potential CDMO partners. 3) Conduct the Annual Vendor Evaluation, assess delivery timeliness, quality, price competitiveness, cooperation, and technical support.
Evaluation Mechanisms /Results	Regularly conduct supplier evaluations. In 2024, performed 10 site visits to raw material suppliers and contract manufacturing organizations.

☐ The results of the 2024 Annual Vendor Evaluation are as follows:

Evaluation ratings are: A: 85–100, B: 61–84, C: 0–60. Supplier rated as B are considered qualified. Those rated as C are required to make improvements before procurement can be resumed.

	Rating	2022	2023	2024
Supplier	A	35	50	38
	B	12	18	16
	C	-	1	1
Number of Evaluations		47	69	55

☐ Foresee Supplier Audit Performance Over the Past Three Years

Overall Supplier Audit	2022	2023	2024
Number of Suppliers	47	69	55
Number of Supplier Self-Evaluations	47	69	55
Overall Supplier Audit Rate (%)	100%	100%	100%

CMC Supplier Audit	2022	2023	2024
Number of Suppliers	46	63	53
Number of Supplier Self-Evaluations	2	0	0
Number of On-Site Supplier Audits	3	11	10
Audit Self-Assessment Rate%	4.35%	-	-
On-Site Audit Rate%	6.52%	17.46%	18.87%

5. Social Inclusion

Employees are a crucial asset to the Company and a key factor in its continued growth and competitiveness. Following the principle of sustainable development, Foresee Pharmaceuticals is dedicated to creating a happy, safe, and equitable workplace. The Company offers competitive salaries and conducts annual employee performance evaluations to ensure that employees can grow alongside the company. Additionally, channels for employee complaints and communication are provided to understand their needs, promote interaction between labor and management, and foster a friendly work environment. Foresee Pharmaceuticals also has a comprehensive training system, regularly organizing various training courses to enhance employees' professional skills and improve their workplace competitiveness. While the Company currently has no labor union, there are employee-elected labor representatives who participate in regular labor-management meetings for two-way communication. Employees are encouraged to speak freely and express their opinions during these meetings, and the Company responds positively to reach a consensus with the workforce.

In fulfilling its corporate social responsibility, the company continues to participate in charitable activities and donate supplies to underprivileged groups, demonstrating its commitment to greater care and contribution to society. In 2024, our resources were dedicated to the following initiatives:

1) Through a donation to the social welfare foundation, we contributed 60 sets of mooncake gift boxes to the disadvantaged groups in August 2024.
2) Donated approximately NT$100,000 in cash or living necessities to 11 organizations, including foundations and social welfare groups in October 2024.

5.1 Human Rights Protection

Foresee is committed to protecting the fundamental human rights of all employees and stakeholders, as well as safeguarding personal privacy data. The Company adheres to international human rights conventions, such as the "Universal Declaration of Human Rights" and the "List of International Labour Organization (ILO) Conventions," as well as relevant regulations under the Labor Standards Act. Through the establishment of internal management guidelines, we implement our human rights policy. Foresee prohibits any form of discrimination, forced labor, and child labor. We provide equal, fair, and reasonable compensation, benefits, and working conditions, ensuring that all employees are treated with fairness, equality, and dignity. We also comply with occupational safety and health regulations by appointing a dedicated Occupational Health and Safety Officer. This ensures the continuous improvement of the work environment, the prevention of accidents, and the reduction of occupational hazards, thereby safeguarding employees' safety and promoting their physical and mental well-being. In addition, the Company implements various human rights policies according to the following management objectives:

Management Objectives	Specific Details	Implementation Status
Create an Equal and Inclusive Workplace	Set up a complaint hotline and email account for employees to report issues, helping to prevent discrimination disputes or harassment.	No incidents of discrimination or harassment occurred this year.
No Child Labor Employed	Explicitly prohibit the employment of child labor to prevent such practices.	No cases of child labor employment occurred this year.
No Forced Labor	Clearly define working hours and regulations for extended hours, monitor employee attendance, eliminate practices of forced or compulsory labor, and ensure compliance with the Labor Standards Act.	The Company implements a vacation policy, encourages employees to maintain a work-life balance, and there have been no incidents of forced or compulsory labor this year.

Management Objectives	Specific Details	Implementation Status
A Healthy and Safe Work Environment	1) Provide health examination subsidies for employees. 2) Provide comprehensive fire safety training.	The Company provides a safe and healthy work environment for employees. Each year, we offer health check subsidies and provide group insurance. Regular safety and health education is conducted, and we actively participate in fire safety seminars and drills organized by the building management committee. There have been no incidents of accidental injuries or occupational accidents this year.
Privacy Protection	Implement Information Security	To protect human rights and privacy, Foresee has implemented comprehensive controls for accessing, processing, transmitting, and storing data, as well as for personnel and equipment security. We have adopted relevant security measures for all aspects, including application system development and maintenance, databases, networks, personal computers, and storage media. There have been no incidents of privacy violations or personal data breaches this year.

5.2 Diversity and Inclusion

Foresee Pharmaceuticals had 68 employees in 2024. Due to the Company's continued growth, the number of employees in all categories has increased over the past three years. Of the 68 employees in 2024, 29 are women, making up 42.65% of the workforce. There are 9 board members, of whom 1 is female, representing 11%. The Company prioritizes professional abilities in recruitment, eliminating gender discrimination, and is committed to a workplace culture of gender equality.

The Company is committed to promoting diversity within the Board of Directors and acknowledges the critical role that gender diversity plays in enhancing corporate governance and the integrity of decision-making processes. Currently, the composition of the Board is determined based on the Company’s scale, industry characteristics, and practical operational requirements. While we recognize the importance of achieving gender diversity targets, these have not yet been met. This is primarily due to the strong performance and high reappointment rate of current board members, which limits the opportunity for structural changes in the short term. To strengthen gender diversity on the Board, the Company will integrate gender representation as a key consideration in the nomination and selection of future board candidates. We are committed to identifying and appointing qualified female professionals and will continue to take proactive measures to enhance the diversity of the Board in alignment with our long-term governance and sustainability goals.

☐ Gender Equality and Diversity

Foresee is committed to providing a respectful and safe work environment for employees. We implement diverse recruitment practices and promote gender equality, ensuring that employees are not subjected to discrimination, harassment, or unequal treatment based on race, gender, religion, age, political orientation, or any other condition protected by applicable laws. We have established relevant “Sexual Harassment Prevention Measures, Complaint Procedures, and Disciplinary Actions.” In addition, the Company respected the cultural customs of the 30 foreign employees in 2024, and there have been no incidents of violations of their work rights or human rights.

Category	Proportion of All Employees (%)	Proportion in Management Levels (%)
ROC Nationality	62	31
Foreign Nationality	38	69

Diversity Statistics				2022		2023		2024	
				People	Percentage	People	Percentage	People	Percentage
Director		Gender	Male	7	87.50%	8	88.89%	8	88.89%
			Female	1	12.50%	1	11.11%	1	11.11%
		Age	Under 50	0	0.00%	0	0.00%	0	0.00%
			50~65	1	12.50%	2	22.22%	2	22.22%
			Over 65	7	87.50%	7	77.78%	7	77.78%
		Education	Doctorate	6	75.00%	7	77.78%	7	77.78%
			Master’s	1	12.50%	1	11.11%	1	11.11%
			Undergraduate	1	12.50%	1	11.11%	1	11.11%
Employees	Direct (R&D)	Gender	Male	26	63.41%	28	62.22%	32	66.67%
			Female	15	36.59%	17	37.78%	16	33.33%
		Age	Under 50	2	4.88%	2	4.44%	3	6.25%
			50~65	27	65.85%	29	64.44%	31	64.58%
			Over 65	12	29.27%	14	31.11%	14	29.17%
		Education	Doctorate	21	51.22%	27	60.00%	28	58.33%
			Master’s	18	43.90%	15	33.33%	15	31.25%
			Undergraduate	2	4.88%	3	6.67%	5	10.42%
	Indirect (Administrative and Business Development)	Gender	Male	7	41.18%	7	35.00%	7	35.00%
			Female	10	58.82%	13	65.00%	13	65.00%
		Age	Under 50	0	0.00%	0	0.00%	0	0.00%
			50~65	13	76.47%	15	75.00%	15	75.00%
			Over 65	4	23.53%	5	25.00%	5	25.00%
		Education	Doctorate	2	11.76%	2	10.00%	2	10.00%
			Master’s	3	17.65%	5	25.00%	5	25.00%
			Undergraduate	12	70.59%	13	65.00%	13	65.00%

Note: Male/Female Board Member Percentage = (Number of Male/Female Board Members in the Year / Total Number of Board Members in the Year) * 100%
Note: Percentage of Employees in a Specific Age Range = (Total Number of Direct Employees in the Specific Age Range / Total Number of Employees in the Year) * 100%
Note: Education Level Percentage = (Total Number of Direct Employees with a Specific Education Level / Total Number of Employees in the Year) * 100%

Local Residents Employed as Senior Management

Key Operational Locations	Senior Executives	Local Residents Employed as Senior Executives	Percentage
Taiwan	2	2	100%
USA	8	8	100%
Canada	1	1	100%

Employee Statistics

Statistics/Year		2022	2023	2024
Total Number of Employees (Note 1)		58	65	68
Employment Contract (Note 2)		Non-fixed	Non-fixed	Non-fixed
Gender	Male	33	35	40
	Female	25	30	28
Location	Taiwan	37	40	42
	Canada	2	1	1
	USA	19	24	25

Note 1: The total number of employees is based on the end of the year (Dec. 31).
Note 2: Employees with non-fixed term employment contracts are considered full-time.

Statistics/Year		2022		2023		2024	
Employment Type (Note)		Full-time	Part-time	Full-time	Part-time	Full-time	Part-time
Gender	Male	32	1	34	1	39	1
	Female	25	0	30	0	28	0
Location	Taiwan	37	0	40	0	42	0
	Canada	2	0	1	0	1	0
	USA	18	1	23	1	24	1

Note: Employment types are categorized as full-time employees (those who work up to the statutory maximum hours per week) and part-time employees (those who work less than the statutory maximum hours per week, limited to the Chief Medical Officer).

Non-Employee Statistics

Statistics/Year		2022	2023	2024
Total Number of Workers (Note)		1	1	3
Contract Type		Appointed	Appointed	Appointed
Gender	Male	1	1	3
	Female	-	-	-
Job Type		Cleaning Staff	Cleaning Staff	Cleaning Staff
Gender	Male	1	1	3
	Female	-	-	-
Location	Taiwan	1	1	3

Note: The total number of workers is based on the end of the year (12/31).





5.3 Talent Attraction and Retention

Talent is the Company's most important asset, serving as well as partners in creating corporate value, and a crucial cornerstone for the Company's continued growth and operations. Innovation in research and development and a people-centric management model are key factors for enhancing the Company's competitiveness. Foresee Pharmaceuticals offers a diverse, open, and respectful work environment that encourages employee self-growth, along with competitive salaries and a range of benefits, to attract interdisciplinary talent and employees who align with the Company's organizational culture and values. Our compensation mechanisms are linked with the Company's operational goals to allow employees and the Company to share in the results. Enhancing employee loyalty to the Company and creating shared corporate value are key components of Foresee's human resources development strategy.

Through fair and transparent recruitment channels, we are committed to finding like-minded talent. During the recruitment process, all candidates are treated equally regardless of race, gender, age, religion, nationality, or political affiliation. We firmly believe that diversity is key to innovation and growth. Hiring should be based on capabilities, and we strongly oppose any form of discrimination. We are dedicated to making Foresee Pharmaceuticals a diverse, innovative, and steadily growing company. Our goal is to create an open and inclusive work environment where everyone can showcase their talents and realize their value.

Due to considerations of personal data protection and confidentiality, the Company has chosen not to disclose information required under GRI 2-21. Nevertheless, the Company fully complies with applicable laws and internal remuneration policies to ensure that its compensation framework remains fair and reasonable. In 2024, the median total annual remuneration of other employees in Taiwan was NTD 1,292 thousand. The ratio of the highest-paid individual's total annual remuneration to this median figure was approximately 1.85. The ratio between the percentage increase in the highest-paid individual's total annual remuneration and the median percentage increase in the average total annual remuneration of other employees was 1.47.

Short-term Goals	1) To promote workforce diversity and increase the proportion of female talent, the company has established multiple recruitment channels, including online job portals, social media platforms, and external recruitment consultants. These efforts have enhanced the efficiency of the recruitment process, reduced the time-to-hire, and broadened access to a more diverse talent pool. As a result, women account for over 40% of new hires. 2) Enhancing employee satisfaction: the annual employee satisfaction survey scored over 80 points. 3) Enhancing employee retention: Achieved an annual employee retention rate of over 85%.
Mid-to Long-term Goals	1) Enhancing retention of key talent: The Company offers a competitive total compensation package to attract and retain top-tier talent, while rewarding employees who deliver outstanding performance and demonstrate long-term commitment. The retention rate of key talent—such as mid- to senior-level managers and R&D personnel—has reached 80%. In addition, over 90% of high-performing employees receive annual adjustments in compensation and benefits. 2) Building a diverse and high-performing talent pipeline: The proportion of female employees in the talent pipeline exceeds 40%. Each year, more than 8% of high-potential employees are successfully promoted to higher-level positions, reflecting the effectiveness of our internal development and succession planning programs. 3) Achieving Talent Retention and Continuous Enhancement of Corporate Culture:The employee turnover rate is maintained below 15%, while employee satisfaction with corporate culture exceeds 85%. The Company continues to focus on work-life balance, providing greater mental health support and workplace flexibility. In addition, sustainability initiatives are strengthened to enhance employees' sense of identification with the Company's social values.
Resources Invested in the Current Year	1) Annual employee health check-ups include 1360 hours of paid leave and a subsidy of NT$80,000. 2) Employee education and training totaled 1,042 hours, with expenses amounting to NT$875,000. 3) Conducted two internal control process briefing sessions for overseas employees. 4) Offer flexible working hours and remote work options based on employees' job responsibilities to maintain work-life balance.
Evaluation Mechanisms/ Results	1) The average and median salaries for full-time employees not in supervisory roles have both increased compared to the previous year. 2) To attract and retain professional talent both domestically and internationally, the Company has approved the issuance of restricted employee stock rights through an extraordinary shareholders' meeting.

5.3.1 Employees and Employee Turnovers

New Employee		2022		2023		2024	
		Total	Percentage (Note)	Total	Percentage (Note)	Total	Percentage (Note)
Age	Under 30	2	3.45%	2	3.08%	3	21.43%
	Over 30, under 50	11	18.97%	7	10.77%	10	71.43%
	Over 50	5	8.62%	5	7.69%	1	7.14%
Gender	Male	10	17.24%	5	7.69%	6	42.86%
	Female	8	13.79%	9	13.85%	8	57.14%
Education	Doctorate	2	3.45%	8	12.31%	2	14.29%
	Master’s	13	22.41%	4	6.15%	5	35.71%
	Undergraduate	3	5.17%	2	3.08%	7	50.00%
Location	Taiwan	9	15.52%	5	7.69%	9	64.29%
	USA	8	13.79%	9	13.85%	5	35.71%
	Canada	1	1.72%	0	0.00%	0	0.00%

Note: New Employee Ratio= (Total Number of New Employees in the Specific Category for the Year / Total Number of Employees in the Specific Category at Year-End) * 100%

Note: Female New Employee Ratio= (Total Number of Female New Employees for the Year / Total Number of Female Employees at Year-End) * 100%

Employee Turnover		2022		2023		2024	
		Total	Percentage (Note)	Total	Percentage (Note)	Total	Percentage (Note)
Age	Under 30	0	0.00%	2	3.08%	1	1.47%
	Over 30, under 50	0	0.00%	2	3.08%	7	10.29%
	Over 50	2	3.45%	3	4.62%	3	4.41%
Gender	Male	2	3.45%	3	4.62%	2	2.94%
	Female	0	0.00%	4	6.15%	9	13.24%
Education	Doctorate	1	1.72%	2	3.08%	1	1.47%
	Master’s	1	1.72%	5	7.69%	5	7.35%
	Undergraduate	0	0.00%	0	0.00%	5	7.35%
Location	Taiwan	1	1.72%	2	3.08%	7	10.29%
	USA	1	1.72%	5	7.69%	4	5.88%
	Canada	0	0.00%	1	1.54%	0	0.00%

Note: Turnover Rate = (Total Number of Employees Departing from the Specific Category for the Year / Total Number of Employees in the Specific Category at Year-End) * 100%

Note: Turnover Rate for Employees Under 30 = (Total Number of Employees Under 30 Leaving for the Year / Total Number of Employees Under 30 at Year-End) * 100%

5.3.2 Compensation and Benefits

The Company has established a "Compensation Structure Policy" and a "Performance Management System." Employee compensation and performance bonuses are determined based on the Company's overall market positioning, industry salary surveys, the industry's growth cycle of the industry, internal equity considerations, and the Company's performance in meeting annual operational goals. These factors, along with the overall market and economic conditions, are reflected in employee salaries and bonuses. Performance bonuses are calculated and distributed based on the score of the Company's annual operational goals, multiplied by the employee's individual performance evaluation. The bonus typically ranges from 10% to 24% of the employee's annual salary. An annual salary adjustment strategy is proposed each year based on the Company's operational performance, market conditions, and the inflation index, with an average increase of approximately 4% to 5%.

◻ Salaries for full-time employees not in supervisory roles

	Employees	Average annual salary		Median annual salary	
		Average of the top 10 in the industry	Foresee	Average of the top 10 in the same industry	Foresee
2022	32	1,124	1,308	1,127	1,119
2023	36	1,287	1,439	1,145	1,237
2024	34	pending announcement	1,541	pending announcement	1,292
Difference	-2		+102		+55

◻ The ratio of entry-level standard wages to local minimum wage by gender

Locations	Gender	Ratio of Standard Wage to Local Minimum Wage
Taiwan	Male	2.7
	Female	1.8

◻ Ratio of female to male base salary plus compensation.

Ratio of base salary plus compensation		2022		2023		2024	
Employee Category	Item	Male	Female	Male	Female	Male	Female
Direct	Base Salary	1.28	1	1.28	1	1.11	1
	Compensation	1.28	1	1.23	1	0.98	1
Indirect	Base Salary	1.41	1	1.36	1	1.13	1
	Compensation	1.40	1	1.37	1	1.11	1

Note: Base salary refers to the minimum fixed amount paid to employees for performing their duties, excluding any additional compensation. The base salary is calculated on a 12-month annual basis.

Note: Compensation refers to the base salary plus any additional amounts paid to workers (including year-end and performance bonuses). An annual fixed year-end bonus equivalent to two months of base salary, in addition to a variable performance-based bonus.

5.3.3 Employee Benefits

Employee Benefits	Full-time Employees	
	Taiwan	USA/Canada
Group Insurance	V	
Marriage/Maternity/Education/ Funeral Subsidies	V	
Year-End/Performance Bonuses	V	
Annual Health Checkup	V	
Company Staff Outing	V	
Employee Stock Ownership	V	
401(k) Retirement Benefit Plan		V

◻ Employee Activities

Parental Leave

Employee Parental Leave	Gender	2022	2023	2024
Eligible for Parental Leave	Male	1	0	0
	Female	0	2	1
Employees Applied for Parental Leave	Male	0	0	0
	Female	0	1	1
Required to Return to Work After Parental Leave Expiration (A)	Male	0	0	0
	Female	0	1	1
Who Returned to Work After Parental Leave Expiration (Including Early Returnees) (B)	Male	0	0	0
	Female	0	1	1
Return-to-Work Rate (B/A)	Male	0	0	0
	Female	0	100%	100%
Employees Returned to Work After Parental Leave and Remained Employed for Twelve Months (C)	Male	0	0	0
	Female	0	0	1
Retention Rate (C/Previous Year B)	Male	-	-	-
	Female	-	-	100%

Note 1: The number of employees eligible for parental leave is based on the number of male and female employees who have applied for maternity or paternity leave in the past three years.
Note 2: Return-to-Work Rate = (Total Number of Employees Who Actually Returned to Work in the Current Year / Total Number of Employees Required to Return to Work in the Current Year) * 100%
Note 3: Retention Rate = (Total Number of Employees Who Returned to Work and Remained Employed for Twelve Months in the Previous Year / Total Number of Employees Who Actually Returned to Work in the Previous Year) * 100%

Employee Retirement Benefits System

Foresee adheres to the "Labor Pension Act," which is a defined contribution retirement scheme. According to the Labor Pension Act, the Company is required to contribute at least 6% of each employee's monthly salary to their individual account at the Bureau of Labor Insurance every month.

Retirement Pension System	New System
Applicable Legal Basis	Labor Pension Act
Contribution Method	Contributed at 6% of employees' insured salary level to individual accounts at the Bureau of Labor Insurance
Contribution Amount	In 2024, the contribution amounted to NT$2,790 thousand

5.4 Talent Development

Foresee Pharmaceuticals values the growth and continuous development of its employees. The Company has established an "Education and Training Management Policy" to encourage employees to continually learn and leverage their strengths. This policy integrates their skills with the Company's development strategy, fostering expertise in their professional or managerial roles to achieve a win-win outcome. In 2024, the total budget for departmental education and training was NT$1,545,000, with actual expenses amounting to NT$875,000. A total of 566 training hours were completed, covering topics such as medical device regulations, new drug development regulations, sustainable governance, core accountability courses, and intellectual property compliance.

Average Training Hours for Employees in Taiwan Over the Past Three Years

Statistics/Year		2022	2023	2024
Average Training Hours Per Employee (Note 1)		9.4	6.9	25
Average Training Hours by Gender (Note 2)	Female	12.8	7.0	28.3
	Male	5.5	6.8	18.0
Average Training Hours by Category (Note 3)	Direct Employees	4.6	3.5	18.6
	Indirect Employees	17.4	12	30.2

Note 1: Average Training Hours Per Employee: Total training hours for all Taiwan employees in the year / Total number of Taiwan employees at year-end.
Note 2: Average Training Hours per Female Employee: Total training hours for female Taiwan employees in the year / Total number of female Taiwan employees at year-end.
Note 3: Average Training Hours for Direct Employees: Total training hours for direct Taiwan employees in the year / Total number of direct Taiwan employees at year-end.

Training Course	Participation	Hours
Corporate Governance/Sustainability/ Ethical Management Related	62	225
Technical/Job Skill Enhancement Related	58	249
Promotion/Seminars	13	59

Employee Performance Evaluation

Annual Performance Evaluation:

1) Each department's direct supervisors conduct annual performance evaluations for their employees.
2) The evaluation uses a “Performance Evaluation Form,” which includes both self-assessment and supervisor assessment sections.
3) Supervisors assess employees based on their performance and relative contributions within the unit.
4) Evaluation Procedure: Self-assessment by employees → Initial evaluation by direct supervisors → Re-evaluation by department heads → Final review and approval by the Chairman → Record retention by the HR department.

2024 Performance Evaluation Statistics		Employees Assessed	Employees in Category	Percentage
Gender	Female	27	28	96%
	Male	38	40	95%
Employee Category	Direct Employees	46	47	98%
	Indirect Employees	19	21	90%

Note: Employee performance evaluations exclude new employees who have been with the Company for less than 3 months during the year (new employees who joined after October 1 are not included in the annual performance evaluation list). Employees who resign during the performance evaluation period are also not included in the evaluation list.

5.5 Business Integrity

Foresee operates based on the principles of fairness, honesty, integrity, and transparency. We have established policies grounded in ethical management, built robust corporate governance and risk control mechanisms, and actively work to prevent dishonest behavior to create a sustainable operating environment. The Company has established the “Procedures for Ethical Management and Guidelines for Conduct” in accordance with the “Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies” and relevant laws applicable to the locations where the Company and its group enterprises operate. These guidelines specifically define the code of conduct for all employees of the Company. In accordance with the “Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies,” designated personnel are responsible for reporting significant information. This information is publicly disclosed on the Information Disclosure Platform and the Company's official website in a timely manner, ensuring transparency in ethical management.

The Company designates the Audit Office as the responsible unit, which reports directly to the Board of Directors. This department handles the following tasks and is required to provide regular reports to the board:

1) Assist in embedding integrity and ethical values into the Company's business strategies and establish anti-corruption ethical management measures in compliance with legal and regulatory frameworks.
2) Conduct periodic analyses and assessments of integrity risks within the business scope, develop anti-corruption plans based on these assessments, and establish standard operating procedures and behavior guidelines for each plan.
3) Design internal organizational structure, staffing, and responsibilities, and implement checks and balances mechanisms for business activities with higher integrity risks within the business scope.
4) Implement and coordinate training and awareness programs related to the Company's integrity policies.
5) Design a whistleblowing system and ensure its effective implementation.
6) Assist the Board of Directors and management in auditing and evaluating the effectiveness of implemented ethical management measures.
7) Prepare and properly maintain documentation on ethical management policies, compliance statements, implementation commitments, and implementation details.

Short-term Goals	1) Regular and ad-hoc training and awareness sessions for directors and relevant internal personnel are arranged. 2) Establishment of a dedicated unit for promoting corporate ethical management is in progress.
Mid- to Long-term Goals	1) Actively implement the evaluation indicators based on the FSC Corporate Governance 3.0 -Sustainable Development Roadmap. 2) Disclose information related to corporate governance and sustainable development in accordance with relevant laws and regulations, and continuously update it to fulfill the duty of due diligence and information disclosure.
Resources Invested in the Current Year	1) In 2024, an insider trading education and advocacy session was held for employees. The session had a total of 31 participants. The presentation was also shared with all employees via email after the meeting for their reference. 2) The implementation of ethical management practices is disclosed in the annual report and on the Market Observation Post System.
Evaluation Mechanisms /Results	No violations related to ethical management were found through internal control self-assessment and internal audit verification.

Specific Measures to Prevent Insider Trading

The Company revised the “Corporate Governance Best Practice Principles” on May 13, 2022 to include regulations prohibiting internal personnel from trading securities based on non-public information. The aforementioned regulations should include stock trading control measures for internal personnel upon obtaining company financial reports or related performance information. These measures must include, but are not limited to, a restriction where directors are prohibited from trading their stocks during a closed period, which is 30 days before the annual financial report announcement and 15 days before the quarterly financial report announcement. The Company has implemented a policy of informing directors, managers, and other internal personnel about this regulation via email. Additionally, before the start of each closed period preceding each quarterly financial report announcement, an email notification is sent to all internal personnel regarding the stock trading prohibition period, ensuring they are aware of the restriction and avoid any unintentional violations.

Additionally, on December 24, 2024, the Company conducted a one-hour educational session for internal employees, with 31 participants in attendance. The course covered topics such as the essential elements of material information, the timing of its recognition, related penalties for legal violations, and an explanation and analysis of trading examples. After the session, the presentation was emailed to all employees, providing a reference for those who were unable to attend.

Whistleblowing Mechanism for Ethical Management

If any employee violates the “Procedures for Ethical Management” or other corporate governance policies, the issue can be reported through the following whistleblowing channels.

Email	audit@foreseepharma.com
Hotline	02-7750-0188 Ext. 7317
Responsible Unit	Audit Office
Website	https://www.foreseepharma.com/zh-tw/investors/2

Appendix 1、GRI Index

- Declaration of Use: Foresee Pharmaceuticals has reported the content for the period from January 1 to December 31, 2024, in accordance with the GRI Standards. There are currently no applicable GRI sector standards.
- GRI 1 Standards Used: Foundation 2021 ★ Material Topics

GRI 2：General Disclosures 2021			
GRI Disclosures		corresponding section	Page
Organization and reporting practices			
2-1	Organization details	1.1 Business Overview	5
2-2	Entities included in the organization's sustainability reporting	About this Report	3
2-3	Reporting period, frequency and contact point	About this Report	3
2-4	Restatements of information	About this Report	3
2-5	External Assurance/Verification	About this Report	3
Activities and workers			
2-6	Activities, value chain and other business relationships	1.1 Business Overview	5
2-7	Employees	5.2 Diversity and Inclusion	32
2-8	Workers who are not employees	5.2 Diversity and Inclusion	32
Governance			
2-9	Governance structure and composition	3.1.1 Diversity and Independence of the Board of Directors	16
2-10	Nomination and selection of the highest governance body	3.1.1 Diversity and Independence of the Board of Directors	16
2-11	Chair of the highest governance body	3.1.4 Board Communication and Conflict of Interest	18
2-12	Role of the highest governance body in overseeing the management of impacts	1.1 Business Overview 1.4 Stakeholder Communication 3.1 Board of Directors	5 / 10 / 16
2-13	Delegation of responsibility for managing impacts	1.1 Business Overview	6
2-14	Role of the highest governance body in sustainability reporting	1.1 Business Overview	6
2-15	Conflicts of interest	3.1.4 Board Communication and Conflict of Interest	18

GRI 2：General Disclosures 2021			
GRI Disclosures		corresponding section	Page
2-16	Communication of critical concerns	1.4 Stakeholder Communication 3.1.4 Board Communication and Conflict of Interest	10 / 18
2-17	Collective knowledge of the highest governance body	3.1.2 Board Performance Evaluation and Continuing Education	17
2-18	Evaluation of the performance of the highest governance body	3.1.2 Board Performance Evaluation and Continuing Education	17
2-19	Remuneration policies	3.1.3 Compensation of Directors and Supervisors	18
2-20	Process to determine remuneration	3.1.3 Compensation of Directors and Supervisors	18
2-21	Annual total compensation ratio	5.3 Talent Attraction and Retention	35
Strategy, policies and practices			
2-22	Statement on sustainable development strategy	Message from the Chairman	4
2-23	Policy commitments	2.1 Innovation and R&D 3.4 Business Performance 4.3 Laboratory Waste Management 4.4 Sustainable Supply Chain Management 5.3 Talent Attraction and Retention 5.5 Business Integrity	11 / 22 29 / 29 35 / 39
2-24	Embedding policy commitments		
2-25	Processes to remediate negative impacts	1.4 Stakeholder Communication	10
2-26	Mechanisms for seeking advice and raising concerns	About this Report	3
2-27	Regulatory Compliance	3.3 Regulatory Compliance	22
2-28	Membership associations	1.1 Business Overview	6
Stakeholder engagement			
2-29	Approach to stakeholder engagement	1.4 Stakeholder Communication	10
2-30	Collective bargaining agreements	Not Applicable/No Relevant Circumstances	-

GRI 3：Material Topics 2021			
GRI Disclosures		corresponding section	Page
Material Topics			
3-1	Process to determine material topics	1.3 Materiality Assessment	8
3-2	List of material topics	1.3 Materiality Assessment	8
Economic Aspect			
★ Economic Performance GRI 3：Material Topics 2021			
3-3	Management of material topics	3.4 Business Performance	22
GRI 201：Economic Performance 2016			
201-1	Direct economic value generated and distributed	3.4 Business Performance	22
201-2	Financial implications and other risks and opportunities due to climate change	4.1 Climate-Related Financial Disclosures	24
201-3	Defined benefit plan obligations and other retirement plans	5.3.3 Employee Benefits	37
201-4	Financial assistance received from government	3.4 Business Performance	22
Market Position			
GRI 202：Market Presence			
202-1	The ratio of entry-level standard wages to local minimum wage by gender	5.3.2 Compensation and Benefits	37
202-2	Number of Local Residents Employed as Senior Management	5.2 Diversity and Inclusion	32
★ R&D Innovation GRI 3：Material Topics 2021			
3-3	Management of material topics	2.1 Innovation and R&D	11
Environmental Aspect			
GRI 305 : Emissions 2016			
305-1	Direct (Scope 1) GHG emissions	4.2 Energy and Water Resource Management	28
305-2	Energy indirect (Scope 2) GHG emissions	4.2 Energy and Water Resource Management	28
305-4	GHG emissions intensity	4.2 Energy and Water Resource Management	28

GRI 3：Material Topics 2021			
GRI Disclosures		corresponding section	Page
305-6	Emissions of ozone-depleting substances (ODS)	Not Applicable/No Relevant Circumstances	-
305-7	Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant air emissions	Not Applicable/No Relevant Circumstances	-
★ Supplier Environmental Assessment GRI 3：Material Topics 2021			
3-3	Management of material topics	4.4 Sustainable Supply Chain Management	29
GRI 308：Supplier Environmental Assessment 2016			
308-1	New suppliers that were screened using environmental criteria	4.4 Sustainable Supply Chain Management	29
308-2	Negative environmental impacts in the supply chain and actions taken	4.4 Sustainable Supply Chain Management	29
★ Laboratory Waste Management GRI 3：Material Topics 2021			
3-3	Management of material topics	4.3 Laboratory Waste Management	29
Social Aspect			
★ Employment GRI 3：Material Topics 2021			
3-3	Management of material topics	5.3 Talent Attraction and Retention	35
GRI 401 : Employment 2016			
401-1	New employees and employee turnover	5.3.1 Employees and Employee Turnovers	36
401-2	Benefits provided to full-time employees that are not provided to temporary or part-time employees	5.3.3 Employee Benefits	37
401-3	Parental Leave	5.3.3 Employee Benefits	37
★ Training and Education GRI 3：Material Topics 2021			
3-3	Management of material topics	5.3 Talent Attraction and Retention	35
GRI 404：Training and Education 2016			
404-1	Average hours of training per year per employee	5.4 Talent Development	38
404-2	Programs for upgrading employee skills and transition assistance programs	5.4 Talent Development	38
404-3	Percentage of employees receiving regular performance and career development reviews	5.4 Talent Development	38

GRI 3：Material Topics 2021			
GRI Disclosures		corresponding section	Page
Diversity and Equal Opportunity			
GRI 405：Diversity and Equal Opportunity 2016			
405-1	Diversity of governance bodies and employees	3.1.1 Diversity and Independence of the Board of Directors 5.2 Diversity and Inclusion	16 / 32
405-2	Ratio of female to male base salary plus compensation.	5.3.2 Compensation and Benefits	37
★ Supplier Environmental Assessment GRI 3：Material Topics 2021			
3-3	Management of material topics	4.4 Sustainable Supply Chain Management	29
GRI 414：Supplier Social Assessment 2016			
414-1	New suppliers that were screened using social criteria	4.4 Sustainable Supply Chain Management	29
414-2	Negative social impacts in the supply chain and actions taken	4.4 Sustainable Supply Chain Management	29
Customer Health and Safety GRI 3：Material Topics 2021			
416-1	Assessment of the health and safety impacts of product and service categories	2.2 Pharmaceutical Safety	12
★ Ethical Management GRI 3：Material Topics 2021			
3-3	Management of material topics	5.5 Business Integrity	35



Appendix 2、SASB Standards

Topics	Code	Metric	Category	Disclosure
Safety of Clinical Trial Participants	HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	Discussion and Analysis	Foresee conducts ongoing monitoring of clinical trials through the Safety Monitoring Team (SMT). The SMT employs a comprehensive internal signal detection mechanism to evaluate potential safety signals that may impact subject safety. In addition, a Data Safety Monitoring Board (DSMB) is established for each ongoing study. Both the DSMB and SMT hold regular quarterly meetings and may convene ad hoc meetings when necessary. Currently, the preparation of periodic safety reports and the reporting of serious adverse events (SAEs) are outsourced to research partners. To date, no clinical trial has been terminated due to any partner's violation of GCP.
	HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1)Voluntary Action Indicated (VAI) and (2)Official Action Indicated (OAI)	Quantitative	In 2025, Foresee successfully completed the FDA GCP inspection with no Form 483 observations issued. The Company currently has no VAI or OAI status.
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Quantitative	Currently, Foresee Pharmaceuticals does not have such incidents.
Access to Medicines	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Discussion and Analysis	Currently, Foresee Pharmaceuticals does not have such incidents.
	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Discussion and Analysis	Currently, Foresee Pharmaceuticals does not have such incidents.
Affordability and Pricing	HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	Quantitative	Currently, Foresee Pharmaceuticals does not have such incidents.
	HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Quantitative	Our product is marketed through a licensing model, with pricing strategies determined and promoted to the end market by our licensing partners. The relevant prices are also set by the licensing partners in accordance with market mechanisms, ensuring reasonableness and fairness.
	HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Quantitative	
Drug Safety	HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	Discussion and Analysis	As of the end of 2024, Foresee's CAMCEVI 42 mg has not been subject to any safety-related notifications, recalls, or cGMP violations.
	HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Quantitative	
	HC-BP-250a.3	Number of recalls issued; total units recalled	Quantitative	
	HC-BP-250a.4	Total amount of product accepted for take-back, reuse, or disposal	Quantitative	
	HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	Quantitative	

<table>
<tr><th>Topics</th><th>Code</th><th>Metric</th><th>Category</th><th>Disclosure</th></tr>
<tr><td rowspan="3">Counterfeit Drugs</td><td>HC-BP-260a.1</td><td>Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting</td><td>Discussion and Analysis</td><td>Foresee’s pharmaceutical products adhere to GMP (Good Manufacturing Practice) and GDP (Good Distribution Practice) regulations throughout the production and packaging processes. Each product package includes a batch number and barcode for product management and traceability, ensuring medication safety.</td></tr>
<tr><td>HC-BP-260a.2</td><td>Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products</td><td>Discussion and Analysis</td><td>The Company has established the “Procedure for Handling Counterfeit and Prohibited Drugs” and the “Product Recall Procedure.” These procedures guide the initiation of product recalls and investigations, with mandatory reporting to regulatory authorities as required.</td></tr>
<tr><td>HC-BP-260a.3</td><td>Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products</td><td>Quantitative</td><td>Currently, Foresee Pharmaceuticals does not have such incidents.</td></tr>
<tr><td rowspan="2">Ethical Marketing</td><td>HC-BP-270a.1</td><td>Total amount of monetary losses as a result of legal proceedings associated with false marketing claims</td><td>Quantitative</td><td>Currently, Foresee Pharmaceuticals does not have such incidents.</td></tr>
<tr><td>HC-BP-270a.2</td><td>Description of code of ethics governing promotion of off-label use of products</td><td>Discussion and Analysis</td><td>Foresee strictly adheres to WHO and national pharmaceutical marketing ethics guidelines and collaborates with established international pharmaceutical partners to ensure compliance with ethical standards in drug marketing.</td></tr>
<tr><td rowspan="2">Employee Recruitment, Development and Retention</td><td>HC-BP-330a.1</td><td>Discussion of talent recruitment and retention efforts for scientists and research and development personnel</td><td>Discussion and Analysis</td><td>Foresee is committed to creating a challenging and continuously learning work environment that attracts top talent from various fields, making the Company a diverse, innovative, and steadily growing enterprise. Provide a competitive overall compensation package to attract and retain top talent, and reward employees for performance and long-term contributions.</td></tr>
<tr><td>HC-BP-330a.2</td><td>(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others</td><td>Quantitative</td><td><table>
<tr><th>2024</th><th>Senior managers (Executives)</th><th>Mid-level managers (Non-managerial supervisory positions)</th><th>Professionals (Researchers)</th><th>Other Employees (Administrative Personnel)</th></tr>
<tr><td>Employees</td><td>12</td><td>15</td><td>34</td><td>18</td></tr>
<tr><td>Departing Employees</td><td>1</td><td>3</td><td>3</td><td>4</td></tr>
<tr><td>Voluntary turnover rate</td><td>1%</td><td>4%</td><td>4%</td><td>6%</td></tr>
<tr><td>Involuntary turnover rate</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr>
</table></td></tr>
<tr><td>Supply Chain Management</td><td>HC-BP-430a.1</td><td>Percentage of (1) entity facilities and (2) Tier I suppliers’ facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of the supply chain and ingredients</td><td>Quantitative</td><td>Foresee is currently not participating in the Rx-360 International Pharmaceutical Supply Chain Consortium program. However, relevant official agencies such as EMA (European Medicines Agency) and TFDA (Taiwan Food and Drug Administration) have established GDP (Good Distribution Practice) guidelines to ensure the proper management and operation of the pharmaceutical supply chain. The Company also conducts annual supplier evaluations to ensure compliance.</td></tr>
<tr><td rowspan="2">Business Ethics</td><td>HC-BP-510a.1</td><td>Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery</td><td>Quantitative</td><td>Currently, Foresee Pharmaceuticals does not have such incidents.</td></tr>
<tr><td>HC-BP-510a.2</td><td>Description of code of ethics governing interactions with health care professionals</td><td>Discussion and Analysis</td><td>Currently, Foresee Pharmaceuticals does not have such incidents.</td></tr>
<tr><td rowspan="2">Activity Metrics</td><td>HC-BP-000.A</td><td>Number of patients treated</td><td>Quantitative</td><td>CAMCEVI 42mg has obtained drug approvals in Europe, the US, Canada, and Taiwan. It has been available for sale in the US since April 2022, and over 7,365 prostate cancer patients have been treated with this medication.</td></tr>
<tr><td>HC-BP-000.B</td><td>Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)</td><td>Quantitative</td><td>https://www.foreseepharma.com</td></tr>
</table>

Appendix 3、TCFD Disclosures

	Disclosures	Corresponding section
1	Describe how the board and management oversee and manage climate-related risks and opportunities.	4.1 Climate-Related Financial Disclosures
2	Describe the impact of climate-related risks and opportunities on the organization's businesses, strategy, and financial planning over the short, medium, and long term.	4.1 Climate-Related Financial Disclosures
3	Describe the impact of extreme weather and transformation actions on the organization's financial planning.	4.1 Climate-Related Financial Disclosures
4	Describe how processes for identifying, assessing, and managing climate related risks are integrated into the organization's overall risk management.	4.1 Climate-Related Financial Disclosures
5	Describe the scenarios used, including the parameters, assumptions, analysis factors, and major financial impacts.	4.1 Climate-Related Financial Disclosures
6	Describe the indicators and targets used to identify and manage both physical and transition risks.	4.1 Climate-Related Financial Disclosures
7	Describe the basis for setting the internal carbon pricing if used as a risk management tool.	The Company is currently not subject to carbon fee collection and has not yet planned to implement an internal carbon pricing mechanism. We will conduct self-assessments and adopt reduction measures in accordance with the relevant regulations and guidelines issued by the competent authorities.
8	Describe the activities covered, the greenhouse gas emission scopes, the time horizon for achieving the targets, and annual progress against the settled climate-related targets; Describe the source and amount of the offset reductions or the number of RECs used as a material component of the plan to achieve the climate-related targets.	The Company has set 2023 as the baseline year. By 2028, we aim to reduce per capita greenhouse gas (GHG) emissions by 10% compared with the baseline year (with the inventory scope covering Scopes 1 and 2). For water resource management, the target is to reduce per capita consumption by 0.5% every three years; and for waste management, to reduce per capita waste generation by 1% every three years. Performance in 2024: (1) GHG emissions increased by 6% due to business expansion. (2) Per capita water consumption decreased by approximately 10%. (3) Per capita waste generation decreased by approximately 32%.
9	Greenhouse gas inventory and assurance status, and reduction targets, strategies, and specific action plans.	4.2 Energy and Water Resource Management

格瑞國際驗證有限公司
GREAT International Certification Co., Ltd.

Independent Assurance Statement Based on 2024 Sustainability Report of Foresee Pharmaceuticals Co., Ltd.

Statement No.:2506011

Foresee Pharmaceuticals Co., LTD. (hereinafter referred to as Foresee) and GREAT International Certification Co., Ltd. (hereinafter referred to as GREAT) are independent companies and organizations. Except for the evaluation and verification of the company's 2024 sustainability report, GREAT has no financial relationship with Foresee.

The purpose of this independent assurance statement (hereinafter referred to as the Statement) is only to serve as the conclusion of guaranteeing the relevant matters within the scope defined in the following relevant Foresee's Sustainability Report, and not for other purposes. Except for the Statement for fact verification, GREAT does not bear any relevant legal or other responsibilities for the use of other purposes, or anyone who reads this Statement.

This Statement is based on the conclusions made by the relevant information verification provided by Foresee to GREAT. Therefore, the scope of the review is based on and limited to the content of the information provided. GREAT believes that the information content is complete, accurate and precise. Any questions about the content of this Statement or related matters will be answered by Foresee.

The Scope of Assurance

The verification scope of Foresee and GREAT agreement includes:

- The contents of the entire sustainability report and all operating performance of Foresee from January 1, 2024 to December 31, 2024;
- According to the type 1 of AA1000 Assurance Standard v3, evaluate the nature and degree of Foresee 's compliance with the AA1000 Accountability Principles (2018), excluding the verification of the reliability of the information/data disclosed in the report.
- This Statement is made in Chinese and translated into English for reference.

Verification Opinion

We summarize the content of Foresee's sustainability report, and provide a fair standpoint of Foresee 's related operations and performance. We believe that the specific performance indicators of Foresee in 2024, such as environment, society and corporate governance, are presented correctly. The performance indicators disclosed in the report demonstrate Foresee's expectations and efforts to identify and satisfy stakeholders.

Our verification work is carried out by a group of teams with verification capabilities according to the AA1000 Assurance Standard v3, as well as the planning and execution of this part of the work to obtain the necessary information data and instructions. We believe that the evidence provided by Foresee is sufficient to show that its reporting method and self-declaration in accordance with the AA1000 Assurance Standard v3 and its 2018 appendix are in line with the GRI Sustainability Reporting Guidelines.

Verification method

To gather the evidence relevant to the conclusions, we performed the following:

- To conduct a senior management review of issues from external parties related to Foresee 's corporate policies to confirm the appropriateness of the statement in this report;
- To discuss with the managers of Foresee about the way of stakeholder participations, and have no direct contact with external stakeholders;
- To interview with employees related to the preparation of the sustainability report and information provision;
- To audit the performance data of Foresee on a sampling basis;
- To evidence supporting the claims made in the review report;
- To Review the management process of the principles of inclusivity, materiality, responsiveness, and impact described in the company report and its related AA1000 Accountability Principles (2018).

Conclusion

The results of a detailed review of the AA1000 Accountability Principles (2018) including inclusivity, materiality, responsiveness, impact and GRI sustainability reporting standards are as follows:

- **Inclusivity**

  Foresee has established a process of cooperation with major stakeholders, including shareholders/investors, employees, drug development collaborative and suppliers, communities/groups and government authorities, etc., and will launch a

Page 1 of 2

格瑞國際驗證有限公司
GREAT International Certification Co., Ltd.

series of stakeholder activities in 2024, involving economy, environment and society, a series of major themes. In terms of our professional opinion, this report covers the inclusivity issues of Foresee.

- **Materiality**

  The report has stated that Foresee focuses on economy, environment and society topics, and identified 6 major topics including innovation R&D, operating performance, integrity management, talent attraction and retention, supply chain sustainability management and laboratory waste management, etc. In terms of our professional opinion, this report appropriately covers the materiality issues of Foresee.

- **Responsiveness**

  Foresee responds to requests and opinions from stakeholders. Implementation methods include annual report, shareholders' meeting, biotechnology exhibition, public information observatory, legal person briefing session, company website, employee performance appraisal, internal E-mail announcement, supplier visits, policy promotion meetings/official documents of competent authorities, phone calls and email, etc., those numerous internal and external stakeholder communication mechanisms, as an opportunity to provide further responses to stakeholders, and to promptly respond to stakeholder concerns. In terms of our professional opinion, this report covers the responsiveness issues of Foresee.

-Impact

Foresee has identified and fairly demonstrated its impact with balanced and effective measurement and disclosure. Foresee has established a process for monitoring, measuring, evaluating and managing impacts, which helps to achieve more effective decision-making and results management within the organization. In terms of our professional opinion, this report covers the impact issues of Foresee.

-GRI Guidelines

Foresee provides the self-declaration of compliance with the GRI Sustainability Reporting Standards and relevant information. Based on the results of the review, we confirm that the report refers to the social responsibility and sustainability of the GRI Sustainability Reporting Standards. Relevant disclosure items for developments have been disclosed, partially disclosed, or omitted. In terms of our professional opinion, this self-declaration covers Foresee 's social responsibility and sustainability themes.

Assurance level

According to the AA1000 Assurance Standard v3 and its 2018 Appendix, we have verified that this Statement is a moderate level of assurance, as described in the scope and methods of this Statement.

Responsibility

The responsibility of the sustainability report, as stated in this Statement, is owned by the person in charge of Foresee. The responsibility of GREAT is solely to provide professional opinions based on the scope and methods described, and to provide a Statement for the stakeholders.

Ability and Independence

GREAT is composed of experts in various management system fields. The verification team is composed of members with professional background, who have received training in a series of sustainable development, environmental and social management standards such as AA1000 AS v3, ISO 9001, ISO 14001 and ISO 45001, and are qualified as lead auditors.

On behalf of the assurance team JUNE 30, 2025

GREAT International Certification Co., Ltd.

Taiwan, Republic of China

Signed by General Manager W. J. Chen

AA1000
Licensed Report
000-250/V3-CKUWD

Page 2 of 2

We develop technologies and medicines that provide patients with better comfort, compliance, convenience and ultimately cures.

9F-2, No. 19-3, Sanchong Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)

+886-2-7750-0188

esg@foreseepharma.com

www.foreseepharma.com